Methods and systems for presenting an inhalation experience

ABSTRACT

Methods, computer program products, and systems are described that include monitoring at least one health attribute of an individual during an artificial sensory experience, associating a characteristic of the artificial sensory experience with the at least one health attribute of the individual, and modifying at least one of an inhalation device-dispensed bioactive agent or the artificial sensory experience at least partially based on associating a characteristic of the artificial sensory experience with the at least one health attribute of the individual.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is related to and claims the benefit of theearliest available effective filing date(s) from the following listedapplication(s) (the “Related Applications”) (e.g., claims earliestavailable priority dates for other than provisional patent applicationsor claims benefits under 35 USC §119(e) for provisional patentapplications, for any and all parent, grandparent, great-grandparent,etc. applications of the Related Application(s)).

RELATED APPLICATIONS

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Dec. 30, 2008, application Ser. No.12/317,934, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Dec. 31, 2008, application Ser. No.12/319,143, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Feb. 12, 2009, application Ser. No.12/378,284, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Feb. 13, 2009, application Ser. No.12/378,485, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Feb. 20, 2009, application Ser. No.12/380,013, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Feb. 23, 2009, application Ser. No.12/380,108, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Feb. 27, 2009, application Ser. No.12/380,587, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Mar. 2, 2009, application Ser. No.12/380,679, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Mar. 25, 2009, application Ser. No.12/383,509, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Mar. 26, 2009, application Ser. No.12/383,819, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Mar. 31, 2009, application Ser. No.12/384,104, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

For purposes of the USPTO extra-statutory requirements, the presentapplication constitutes a continuation-in-part of U.S. PatentApplication entitled METHODS AND SYSTEMS FOR PRESENTING AN INHALATIONEXPERIENCE, naming RODERICK A. HYDE; ROBERT LANGER; ERIC C. LEUTHARDT;ROBERT W. LORD; ELIZABETH A. SWEENEY; CLARENCE T. TEGREENE; AND LOWELLL. WOOD as inventors, filed Apr. 1, 2009, application Ser. No.12/384,203, which is currently co-pending, or is an application of whicha currently co-pending application is entitled to the benefit of thefiling date.

The United States Patent Office (USPTO) has published a notice to theeffect that the USPTO's computer programs require that patent applicantsreference both a serial number and indicate whether an application is acontinuation or continuation-in-part. Stephen G. Kunin, Benefit ofPrior-Filed Application, USPTO Official Gazette Mar. 18, 2003, availableat http://www.uspto.gov/web/offices/com/sol/og/2003/week11/patbene.htm.The present Applicant Entity (hereinafter “Applicant”) has providedabove a specific reference to the application(s) from which priority isbeing claimed as recited by statute. Applicant understands that thestatute is unambiguous in its specific reference language and does notrequire either a serial number or any characterization, such as“continuation” or “continuation-in-part,” for claiming priority to U.S.patent applications. Notwithstanding the foregoing, Applicantunderstands that the USPTO's computer programs have certain data entryrequirements, and hence Applicant is designating the present applicationas a continuation-in-part of its parent applications as set forth above,but expressly points out that such designations are not to be construedin any way as any type of commentary and/or admission as to whether ornot the present application contains any new matter in addition to thematter of its parent application(s).

All subject matter of the Related Applications and of any and allparent, grandparent, great-grandparent, etc. applications of the RelatedApplications is incorporated herein by reference to the extent suchsubject matter is not inconsistent herewith.

TECHNICAL FIELD

This description relates to methods and systems for an inhaled bioactiveagent combined with an artificial sensory experience.

SUMMARY

In one aspect, a method includes but is not limited to monitoring atleast one health attribute of an individual during an artificial sensoryexperience, associating a characteristic of the artificial sensoryexperience with the at least one health attribute of the individual, andmodifying at least one of an inhalation device-dispensed bioactive agentor the artificial sensory experience at least partially based onassociating a characteristic of the artificial sensory experience withthe at least one health attribute of the individual. In addition to theforegoing, other method aspects are described in the claims, drawings,and text forming a part of the present disclosure.

In one or more various aspects, related systems include but are notlimited to circuitry and/or programming for effecting theherein-referenced method aspects; the circuitry and/or programming canbe virtually any combination of hardware, software, and/or firmwareconfigured to effect the herein-referenced method aspects depending uponthe design choices of the system designer.

In one aspect, a system includes but is not limited to means formonitoring at least one health attribute of an individual during anartificial sensory experience, means for associating a characteristic ofthe artificial sensory experience with the at least one health attributeof the individual, and means for modifying at least one of an inhalationdevice-dispensed bioactive agent or the artificial sensory experience atleast partially based on associating a characteristic of the artificialsensory experience with the at least one health attribute of theindividual. In addition to the foregoing, other method aspects aredescribed in the claims, drawings, and text forming a part of thepresent disclosure.

In one aspect, a system includes but is not limited to circuitry formonitoring at least one health attribute of an individual during anartificial sensory experience, circuitry for associating acharacteristic of the artificial sensory experience with the at leastone health attribute of the individual, circuitry for modifying at leastone of an inhalation device-dispensed bioactive agent or the artificialsensory experience at least partially based on associating acharacteristic of the artificial sensory experience with the at leastone health attribute of the individual. In addition to the foregoing,other method aspects are described in the claims, drawings, and textforming a part of the present disclosure.

In one aspect, a computer program product includes but is not limited toa signal-bearing medium bearing one or more instructions for monitoringat least one health attribute of an individual during an artificialsensory experience, one or more instructions for associating acharacteristic of the artificial sensory experience with the at leastone health attribute of the individual, and one or more instructions formodifying at least one of an inhalation device-dispensed bioactive agentor the artificial sensory experience at least partially based onassociating a characteristic of the artificial sensory experience withthe at least one health attribute of the individual. In addition to theforegoing, other method aspects are described in the claims, drawings,and text forming a part of the present disclosure.

In one aspect, a system includes but is not limited to a computingdevice and instructions that when executed on the computing device causethe computing device to monitor at least one health attribute of anindividual during an artificial sensory experience, associate acharacteristic of the artificial sensory experience with the at leastone health attribute of the individual, and modify at least one of aninhalation device-dispensed bioactive agent or the artificial sensoryexperience at least partially based on associating a characteristic ofthe artificial sensory experience with the at least one health attributeof the individual. In addition to the foregoing, other method aspectsare described in the claims, drawings, and text forming a part of thepresent disclosure.

The foregoing is a summary and thus may contain simplifications,generalizations, inclusions, and/or omissions of detail; consequently,those skilled in the art will appreciate that the summary isillustrative only and is NOT intended to be in any way limiting. Otheraspects, features, and advantages of the devices and/or processes and/orother subject matter described herein will become apparent in theteachings set forth herein.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 2 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 3 illustrates an exemplary inhalation device.

FIG. 4 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 5 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 6 illustrates an operational flow representing example operationsrelated to combining an inhaled bioactive agent and an artificialsensory experience.

FIG. 7 illustrates an alternative embodiment of the operational flow ofFIG. 6.

FIG. 8 illustrates an alternative embodiment of the operational flow ofFIG. 6.

FIG. 9 illustrates an alternative embodiment of the operational flow ofFIG. 6.

FIG. 10 illustrates an alternative embodiment of the operational flow ofFIG. 6.

FIG. 11 illustrates an alternative embodiment of the operational flow ofFIG. 6.

FIG. 12 illustrates an alternative embodiment of the operational flow ofFIG. 6.

FIG. 13 illustrates an alternative embodiment of the operational flow ofFIG. 6.

FIG. 14 illustrates an alternative embodiment of the operational flow ofFIG. 6.

FIG. 15 illustrates an alternative embodiment of the operational flow ofFIG. 6.

FIG. 16 illustrates a computer program product related to combining aninhaled bioactive agent and an artificial sensory experience.

FIG. 17 illustrates a system related to combining an inhaled bioactiveagent and an artificial sensory experience.

FIG. 18 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 19 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 20 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 21 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 22 illustrates an operational flow representing example operationsrelated to combining an inhaled bioactive agent and an artificialsensory experience.

FIG. 23 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 24 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 25 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 26 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 27 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 28 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 29 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 30 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 31 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 32 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 33 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 34 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 35 illustrates an alternative embodiment of the operational flow ofFIG. 22.

FIG. 36 illustrates a computer program product related to combining aninhaled bioactive agent and an artificial sensory experience.

FIG. 37 illustrates a system related to combining an inhaled bioactiveagent and an artificial sensory experience.

DETAILED DESCRIPTION

In the following detailed description, reference is made to theaccompanying drawings, which form a part hereof. In the drawings,similar symbols typically identify similar components, unless contextdictates otherwise. The illustrative embodiments described in thedetailed description, drawings, and claims are not meant to be limiting.Other embodiments may be utilized, and other changes may be made,without departing from the spirit or scope of the subject matterpresented here.

FIG. 1 illustrates system 100 for accepting an indication of at leastone health-related condition and/or presenting an indication of at leastone artificial sensory experience and an indication of at least oneinhalation therapy at least partially based on the accepting at leastone indication of a health-related condition. The system 100 may includeaccepter module 102, presenter module 104, and/or administration unit106. Administration unit 106 may include physical intervention effectormodule 108 and/or artificial sensory experience effector module 120.Physical intervention effector module 108 may include inhalation device110. Inhalation device 110 may include inhalation collar 112 and/orvirtual reality headset 114. Additionally, system 3200 may includemobile device 132.

FIG. 2 illustrates system 100 for accepting an indication of at leastone health-related condition and/or presenting an indication of at leastone artificial sensory experience and an indication of at least oneinhalation therapy at Least partially based on the accepting at leastone indication of a health-related condition. The system 100 may includeaccepter module 102, presenter module 104, administration unit 106,and/or monitoring unit 3202. Accepter module 102 may receive and/ortransmit information and/or data to and/or from user 118, database 122,presenter module 3410, output device 130, and/or health care provider136. Database 122 may include medication database 124 and/or artificialsensory experience database 126. Monitoring unit 3202 may monitorindividual 134 and may include drug sensing unit 3204, physiologicactivity monitor 3206, brain activity measurement unit 3208, behaviormonitor 3210, instrumentation monitor 3212, compliance reporting unit3214, voice response module 3216, hearing test module 3218, and/or scale3220. Administration unit 106 may include physical intervention effectormodule 108 and/or artificial sensory experience effector module 120.Physical intervention effector module 108 may include inhalation device110. Inhalation device 110 may include inhalation collar 112 and/orvirtual reality headset 114. Additionally, mobile device 132 maycommunicate with accepter module 102, presenter module 104, healthcareprovider 136, user 118, individual 134, monitoring unit 3202, and/oradministration unit 3222.

FIG. 3 illustrates an exemplary inhalation device 110. An exemplaryinhalation device 110 may include a closure device, a transducer, and/ora dispensing reservoir. Inhalation device 110 may include, for example,a collar, a necklace, and/or a bracelet. Inhalation device 110 mayinclude tubing, a chain, a polymer, a metal, a textile, and may be solidand/or hollow. Closure device 302 may include a buckle, Velcro, a snap,a clasp, a lock, a coupler, elastic, and/or magnets. Transducer 304 mayinclude a blood glucose monitor, a blood oxygen monitor, means forsending a signal to a reservoir to dispense medication, such as anantenna, means for powering the unit, such as a battery, memory, and/ora computer processor. Dispensing reservoir 306 may include means forpower, such as a battery, means for receiving conditional input, such asa processor and/or memory, means for dispensing a bioactive agent inaerosol, dust and/or vapor form, such as a nebulizer, a sprayer, and/ora nozzle. Additionally, the dispensing reservoir 306 may be removableand/or refillable.

FIG. 4 further illustrates system 100 including accepter module 102and/or presenter module 104. Accepter module 102 may include computerinterfacing accepter module 402, inhalation collar indication acceptermodule 406, headset indication accepter module 408, schedule acceptermodule 410, inhalation device accepter module 412, unregulated deviceaccepter module 418, and/or recreational device accepter module 420.Computer interfacing accepter module 402 may include wireless acceptermodule 404. Inhalation device accepter module 412 may includeprescription medicine device accepter module 414 and/or prescriptionmedicine accepter module 416. Recreational device accepter module 420may include recreational compound indication accepter module 422.

FIG. 5 illustrates system 100 including accepter module 102 and/orpresenter module 104. Presenter module 104 may include prescriptionartificial sensory experience presenter module 424, algorithm utilizermodule 440, medical history indication presenter module 444,experimental indiciation presenter module 446, reference tool indicationpresenter module 448, output device presenter module 450, and/or thirdparty presenter module 456. Prescription artificial sensory experiencepresenter module 424 may include artificial sensory experience presentermodule 426, artificial sensory experience effect presenter module 428,effectiveness change presenter module 434, concentration changepresenter module 436, and/or recommender module 438. Artificial sensoryexperience effect presenter module 428 may include artificial sensoryexperience desired effect presenter module 430 and/or artificial sensoryexperience adverse effect presenter module 432. Algorithm utilizermodule 440 may include contraindication algorithm utilizer module 442.Output device presenter module 450 may include user interface presentermodule 452 and/or mobile device presenter module 454. Third partypresenter module 456 may include health care provider presenter module458 and/or selective presenter module 460.

FIG. 6 illustrates an operational flow 600 representing exampleoperations related to accepting an indication of at least onehealth-related condition and presenting an indication of at least oneartificial sensory experience and an indication of at least oneinhalation therapy at least partially based on the accepting at leastone indication of a health-related condition. In FIG. 6 and in followingfigures that include various examples of operational flows, discussionand explanation may be provided with respect to the above-describedexamples of FIGS. 1 through 5, and/or with respect to other examples andcontexts. However, it should be understood that the operational flowsmay be executed in a number of other environments and contexts, and/orin modified versions of FIGS. 1 through 5. Also, although the variousoperational flows are presented in the sequence(s) illustrated, itshould be understood that the various operations may be performed inother orders than those which are illustrated, or may be performedconcurrently.

After a start operation, the operational flow 600 moves to operation610. Operation 610 depicts accepting an indication of at least onehealth-related condition. For example, as shown in FIGS. 1 through 5,accepter module 102 may accept an indication of a bioactiveagent-dispensing inhalation device. One example of a bioactiveagent-dispensing inhalation device may include an inhaler used fordelivering a bioactive agent into the body using a body airway. Someother examples may include a collar, necklace, and/or a bracelet with abioactive agent dispenser proximate to the nose, mouth, and/orinhalation route. In one embodiment, accepter module 102 may accept anindication of a bioactive agent-dispensing collar for dispensing amedication, such as a steroid and/or a bronchodilator. In someinstances, accepter module 102 may include a computer processor, a userinterface, and/or computer memory.

Then, operation 620 depicts presenting an indication of at least oneartificial sensory experience and an indication of at least oneinhalation therapy at least partially based on the accepting at leastone indication of a health-related condition. For example, as shown inFIGS. 1 through 5, presenter module 104 may present an indication of avirtual world at least partially based on accepting an indication of abioactive agent-dispensing inhalation device. One example of anartificial sensory experience may include a virtual world and/or othercomputer-simulated experience. Other examples of an artificial sensoryexperience may include experiences triggering sight, smell, hearing,touch, and/or taste. For example, presenter module 104 may present anindication of an artificial sensory experience including a virtual scentenvironment, which may include olfactory stimulation for improvingmemory. In an additional embodiment, presenter module 104 may present anindication of an artificial sensory experience including a virtualexperience where the user is exposed to a virtual mountain environmentcoupled with a bronchodilator dose from a bioactive agent-dispensinginhalation collar. In this embodiment, the combination bronchodilatorand virtual world treatment may serve to help an asthma sufferer tolearn effective breathing techniques. Presenting an indication of anartificial sensory experience may include presenting the indication to aphysician, to a computer monitor, to a mobile device, and/or to a thirdparty. In some instances, presenter module 104 may include a computerprocessor and/or a communication device, such as a printer, a computermonitor, and/or a speaker.

FIG. 7 illustrates alternative embodiments of the example operationalflow 600 of FIG. 6. FIG. 7 illustrates example embodiments whereoperation 610 may include at Least one additional operation. Additionaloperations may include operation 702, operation 704, operation 706,and/or operation 708.

Operation 702 illustrates accepting an indication of a health-relatedphysical condition. For example, as shown in FIGS. 1 through 5, computerinterfacing accepter module 402 may accept an indication of a bioactiveagent-dispensing inhalation device configured to interface with acomputing device. In one embodiment, computer interfacing acceptermodule 402 may accept an indication of a bioactive agent-dispensinginhalation device configured to interface with a virtual game, such asWorld of Warcraft. Some examples of a computing device may include apersonal computer, a virtual-reality helmet and/or headset, and/or avirtual environment. In some instances, computer interfacing acceptermodule 402 may include a computer processor.

Further, operation 704 illustrates accepting an indication of abioactive agent-dispensing inhalation device configured to interfacewirelessly with a computing device. For example, as shown in FIGS. 1through 5, wireless accepter module 404 may accept an indication of abioactive agent-dispensing inhalation device configured to interfacewirelessly with a computing device. In one embodiment, wireless acceptermodule 404 may accept an indication of a wireless inhalation collarconfigured to interface wirelessly with a computer coupled to wirelessvideo glasses. In this embodiment, both the inhalation collar and thevideo glasses may be wirelessly connected to the computer. The wirelessbioactive agent-dispensing inhalation device may be wirelessly coupledto a computing device using, for example, an IEEE 802.11 computernetwork and/or a Bluetooth wireless sensor network. One example ofwireless video glasses may include Qingbar GP300 video glasses availablefrom 22moo International Pty Ldt., Cabramatta NSW, Australia. In someinstances, wireless accepter module 404 may include a computer processorand/or a wireless receiving device, such as a receiving antenna.

Operation 706 illustrates accepting an indication a health-relatedcondition from a medical history. For example, as shown in FIGS. 1through 5, inhalation collar indication accepter module 406 may acceptan indication of a bioactive agent-dispensing inhalation collar. Abioactive agent-dispensing inhalation collar may include a collar with,for example, means for dispensing a bioactive agent, such as a reservoirand/or an accompanying valve and spray nozzle. Additionally, means fordispensing a bioactive agent may include means for dispensing anaerosol, vapor, a powder (e.g. pulmicort and/or foradil), and/or a mist,such as a nebulizer, means for measuring and/or detecting a condition,such as blood oxygen level and/or body temperature, and/or means forprocessing information, such as a computer processor and/or computermemory. Further, a bioactive agent may be dispensed and/or dispersed inand/or include a surfactant. In one embodiment, inhalation collarindication accepter module 406 may accept an indication of a bioactiveagent-dispensing collar having means for dispensing a steroid as anaerosol. Further, a bioactive agent-dispensing inhalation collar mayinclude means for power, such as a battery and/or circuitry forreceiving power from an external source, such as an AC adapter powersupply. In some instances, inhalation collar indication accepter module406 may include a computer processor.

Operation 708 illustrates accepting an indication of a bioactiveagent-dispensing virtual-reality headset. For example, as shown in FIGS.1 through 5, headset indication accepter module 408 may accept anindication of a bioactive agent-dispensing virtual-reality headset. Avirtual-reality headset may include a microphone, headphones or speakersfor hearing, and/or a display. A virtual-reality headset may beconfigured for enabling a user to engage in an artificial sensoryexperience including sound, smell, and/or sight. One example of avirtual-reality headset may include a virtual reality helmet configuredto give the user a 360° view of a mountain landscape while dispensing abronchodilator for helping the user learn improved breathing techniques.Another example of a virtual reality head set may include an OlympusEye-Trek FMD-200-TFT active matrix head mounted display with Speaker,available from Olympus America Inc., Center Valley Pa. In someinstances, headset indication accepter module 408 may include a computerprocessor.

FIG. 8 illustrates alternative embodiments of the example operationalflow 600 of FIG. 6. FIG. 8 illustrates example embodiments where theoperation 610 may include at least one additional operation. Additionaloperations may include an operation 802, an operation 804, an operation806, and/or an operation 808.

Operation 802 illustrates accepting an indication of a health-relatedmental condition. For example, as shown in FIGS. 1 through 5, scheduleaccepter module 410 may accept at least one of a bioactive agent dosingschedule or a bioactive agent administration schedule. Accepting abioactive agent dosing schedule or a bioactive agent administrationschedule may include accepting from a computer processor, accepting froma memory device, and/or accepting from a user input. In one embodiment,schedule accepter module 410 may accept a dosing schedule specifying abronchoditator administration dosage for a specified time period, suchone dose from an inhalation device once every thirty minutes. In anotherembodiment, schedule accepter module 410 may accept a bioactive agentadministration schedule specifying at least one time a bronchodilatormay be administered. In some instances, schedule accepter module 410 mayinclude a computer processor.

Operation 804 illustrates accepting an indication of amedicine-dispensing inhalation device. For example, as shown in FIGS. 1through 5, inhalation device accepter module 412 may accept anindication of a medicine-dispensing inhalation device. Amedicine-dispensing inhalation device may include a device fordispensing a substance for treating a disease and/or illness. Forexample, a medicine-dispensing inhalation device may include an inhaleras described in Robertson et at., U.S. Pat. No. 7,383,837, which isincorporated herein by reference. Some other examples may include ametered-dose inhaler, a dry powder inhaler, and/or a nebulizer. In oneembodiment, inhalation device accepter module 412 may accept anindication of a medicine-dispensing metered-dose inhaler configured todispense albuterol. In some instances, inhalation device accepter module412 may include a computer processor.

Further, operation 806 illustrates accepting an indication of ahealth-related condition from a user input. For example, as shown inFIGS. 1 through 5, prescription medicine device accepter module 414 mayaccept an indication of a prescription medicine-dispensing inhalationdevice. A prescription medicine-dispensing inhalation device may includea device configured to dispense a medication only available from alicensed health care provider. Some examples of a prescriptionmedication available from a licensed health care provider may includealbuterol, coricosteroids, nitrous oxide, a benzodiazepine,Theophylline, nedocromil sodium, and/or fluticasone/salmeterol. In oneembodiment, prescription medicine device accepter module 414 may acceptan indication of a prescription medicine-dispensing inhalation deviceconfigured for dispensing ciclesonide. In some instances, prescriptionmedicine device accepter module 414 may include a computer processor.

Further, operation 808 illustrates indication of at least one of aprescribed artificial sensory experience or a prescribed inhalationtherapy. For example, as shown in FIGS. 1 through 5, prescriptionmedicine accepter module 416 may accept an indication of at least one ofa steroid, a bronchodilator, menthol, nitrous oxide, a benzodiazepine,or halothane. One example of a steroid may include an anabolic steroid,which may be a derivative of androgens (such as testosterone), forstimulating growth. Another example of a steroid may include acorticosteroid, which may be often used as an anti-inflammatoryprescribed for asthma. A bronchodilator may include a substance thatdilates the bronchi and bronchioles decreasing airway resistance andthereby facilitating airflow. Menthol may include an organic and/orsynthetic compound with local anesthetic and counterirritant qualitiesoften used for relieving throat irritation and/or as a decongestant.Nitrous oxide may include a gas often used as a weak general anesthetic.A benzodiazepine may include a class of psychoactive drugs with varyinghypnotic, sedative, anxiolytic, anticonvulsant, muscle relaxant andamnesic properties, which may be mediated by slowing down the centralnervous system. In one embodiment, prescription medicine accepter module416 may accept an indication of a benzodiazepine. One example ofbenzodiazepine delivery through an inhalation route may be disclosed inKim et at., U.S. Patent Publication No. 2003/0032638, which isincorporated herein by reference. An anti-allergic agent may include anagent configured to block the action of allergic mediators and/or toprevent activation of cells and degranulation processes. Some examplesof an anti-allergic agent may include an antihistamine and/or cromoneslike mast cell stabilizers, such as cromoglicic acid and nedocromilsodium. A muscle relaxant may include a bioactive agent for affectingskeletal muscle function and/or decreasing muscle tone. One example of askeletal muscle relaxant may include carisoprodol. Additionally, amuscle relaxant may include a smooth muscle relaxant. One example of asmooth muscle relaxant may include a methylxanthine, such asTheophylline. An anesthetic may include an inhalational generalanesthetic, such as halothane, desflurane, enflurane, isoflurane, and/orsevoflurane. In some instances, prescription medicine accepter module416 may include a computer processor.

FIG. 9 illustrates alternative embodiments of the example operationalflow 600 of FIG. 6. FIG. 9 illustrates example embodiments where theoperation 610 may include at least one additional operation. Additionaloperations may include an operation 902, an operation 904, and/or anoperation 906.

Operation 902 illustrates accepting an indication of an unregulatedbioactive agent-dispensing inhalation device. For example, as shown inFIGS. 1 through 5, unregulated device accepter module 418 may accept anindication of an unregulated bioactive agent-dispensing inhalationdevice. In one embodiment, unregulated device accepter module 418 mayaccept an indication of an oxygen-dispensing inhalation device. Someexamples of an unregulated bioactive agent may include oxygen, aromasused for aromatherapy, and/or menthol. In another embodiment,unregulated device accepter module 418 may accept an indication of anaromatherapeutic-dispensing inhalation collar. In some instances,unregulated device accepter module 418 may include a computer processor.

Operation 904 illustrates accepting an indication of a recreationalbioactive agent-dispensing inhalation device. For example, as shown inFIGS. 1 through 5, recreational device accepter module 420 may accept anindication of a recreational bioactive agent-dispensing inhalationdevice. In one embodiment, recreational device accepter module 420 mayaccept an indication of a recreational bioactive agent-dispensinginhalation device. Some examples of a recreational bioactive agent mayinclude an aroma compound used for aromatherapy and/or artificial smoke.Other examples of a recreational bioactive agent may include incenseand/or smoke, such as incense and/or smoke used in a religious rite. Insome instances, recreational device accepter module 420 may include acomputer processor.

Further, operation 906 illustrates accepting an indication of at leastone artificial smoke or an aroma compound. For example, as shown inFIGS. 1 through 5, recreational compound indication accepter module 422may accept an indication of at least one artificial smoke or an aromacompound. In one embodiment, recreational compound indication acceptermodule 422 may accept an indication of artificial smoke whileexperiencing a virtual world. In another embodiment, recreationalcompound indication accepter module 422 may accept an indication oflemon oil while experiencing an artificial sensory experience. In thisembodiment, the use of lemon oil as an aromatherapeutic may serve toenhance a user's mood and/or provide relaxation. In some instances,recreational compound indication accepter module 422 may include acomputer processor.

FIG. 10 illustrates alternative embodiments of the example operationalflow 600 of FIG. 6. FIG. 10 illustrates example embodiments whereoperation 620 may include at least one additional operation. Additionaloperations may include operation 1002, operation 1004, operation 1006,operation 1008, and/or operation 1010.

Operation 1002 illustrates indication of at least one of a prescribedartificial sensory experience or a prescribed inhalation therapy. Forexample, as shown in FIGS. 1 through 5, prescription artificial sensoryexperience presenter module 424 may present an indication of aprescribed artificial sensory experience. A prescribed artificialsensory experience may include any artificial sensory experienceprescribed by a health care professional, such as a physician, a mentalhealth specialist, a nurse, a physical therapist, an occupationaltherapist, a chiropractor, and/or a homeopathic practitioner. In oneembodiment, prescription artificial sensory experience presenter module424 may present an indication of a virtual world prescribed by apsychiatrist. In this embodiment, the prescribed virtual world may beconfigured to be administered in conjunction with a prescribed bioactiveagent. Administering a prescribed bioactive agent in conjunction with aprescribed artificial sensory experience may serve to increase efficacyof the combined therapy, for example, by serving as a distraction frompain. In some instances, prescription artificial sensory experiencepresenter module 424 may include a computer processor and/or a displaydevice, such as a computer monitor and/or a printer.

Further, operation 1004 illustrates an indication of at least one of avirtual world experience, a massively multiplayer online game, or alearning tutorial. For example, as shown in FIGS. 1 through 5,artificial sensory experience presenter module 426 may present anindication of a virtual world experience, a massively multiplayer onlinegame, or a Learning tutorial. A virtual world experience may include acomputer-based simulated environment intended to be interactive. Someexamples of a virtual world experience may include a text-based chatroom, computer conferencing, an online game, a single player game,and/or a computer tutorial. A massively multiplayer online game mayinclude a video game capable of supporting multiple players, such asWorld of Warcraft and/or SecondLife. Additionally, a massivelymultiplayer online game may include an experience, such as a game, whichmay include a video game or other interactive experience involvingnumbers of individuals, for example, a religious ceremony or combattraining exercise. An online learning tutorial may include a screenrecording, a written document (either online or downloadabte), or anaudio file, where a user may be given step by step instructions on howto do something. In one embodiment, artificial sensory experiencepresenter module 426 may present an indication of a virtual worldexperience, such as World of Warcraft. In some instances, artificialsensory experience presenter module 426 may include a computerprocessor.

Further, operation 1006 illustrates indication of at least one effect ofthe indication of at least one of a prescribed artificial sensoryexperience. For example, as shown in FIGS. 1 through 5, artificialsensory experience effect presenter module 428 may present an indicationof at least one effect of the prescribed artificial sensory experience.In one embodiment, artificial sensory experience effect presenter module428 may present an indication of at Least one effect of the prescribedartificial sensory experience. An effect may include a reaction and/orthing that occurs as a result of the artificial sensory experience. Forexample, an effect may include a side effect, a desired effect, and/oran adverse effect. Some examples of an effect may include an increasedbioactive agent efficacy, dizziness, and/or a decreased heart rate. Insome instances, artificial sensory experience effect presenter module428 may include a computer processor.

Further, operation 1008 illustrates presenting an indication of at leastone expected desired effect of the prescribed artificial sensoryexperience. For example, as shown in FIGS. 1 through 5, artificialsensory experience desired effect presenter module 430 may present anindication of at least one desired effect of the prescribed artificialsensory experience. Some examples of a desired effect may includeeffects such as an increased bioactive agent efficacy, a cured illnessand/or condition, and/or a changed behavior. In one embodiment,artificial sensory experience desired effect presenter module 430 maypresent an indication of an increased opioid efficacy measured by selfpain evaluation by an individual. In some instances, artificial sensoryexperience desired effect presenter module 430 may include a computerprocessor and/or a display, such as a monitor and/or a printer.

Further, operation 1010 illustrates an indication of at least oneprescribed inhalation therapy. For example, as shown in FIGS. 1 through5, artificial sensory experience adverse effect presenter module 432 maypresent an indication of an expected adverse effect of the prescribedartificial sensory experience. An adverse effect may include a harmfuland/or undesired effect resulting from an intervention, such as anartificial sensory experience. Some examples of an adverse effect mayinclude headache, dizziness, depression, bleeding, seizure, and/orfever. In one embodiment, artificial sensory experience adverse effectpresenter module 432 may present an indication of fever in an individualwhile being administered a prescribed artificial sensory experience andbioactive agent. In some instances, artificial sensory experienceadverse effect presenter module 432 may include a computer processor, adisplay device, such as a monitor and/or printer, and/or medicalinstrumentation, such as a thermometer configured for measuring a bodytemperature.

FIG. 11 illustrates alternative embodiments of the example operationalflow 600 of FIG. 6. FIG. 11 illustrates example embodiments whereoperation 620 may include at least one additional operation. Additionaloperations may include operation 1102, operation 1104, and/or operation1106.

Operation 1102 illustrates an indication of at least one prescribedbioactive agent. For example, as shown in FIGS. 1 through 5,effectiveness change presenter module 434 may present an indication ofat least one time period of an expected change in bioactive agenteffectiveness. In one embodiment, effectiveness change presenter module434 may present an indication of a time period when an opioid isexpected to decrease in effectiveness. Such an indication of decreaseand/or change in bioactive agent effectiveness may serve to indicate anappropriate time period for administering and/or modifying an artificialsensory experience to compensate for a change in bioactive agentefficacy. In another embodiment, effectiveness change presenter module434 may present an indication of a time period where a blood streammorphine concentration drops. This time period of low blood streammorphine concentration may be appropriate for presenting an immersivevirtual world for serving as a distraction to any increase in paincaused by lowered morphine concentration. In some instances,effectiveness change presenter module 434 may include a computerprocessor.

Further, operation 1104 illustrates an indication of at least one timeperiod of an expected change in bioactive agent blood concentration. Forexample, as shown in FIGS. 1 through 5, concentration change presentermodule 436 may present an indication of at least one time period of anexpected change in bioactive agent blood concentration. In oneembodiment, concentration change presenter module 436 may present anindication of a one hour time period of an expected change inhydrocodone blood concentration. Indicating a time period of a change inblood concentration may serve to help determine an artificial sensoryexperience administration schedule. For example, if a bioactive agentblood concentration is expected to be reduced during a certain timeperiod, an artificial sensory experience configured for distracting anindividual from pain may be selected for administration during that timeperiod. In some instances, concentration change presenter module 436 mayinclude a computer processor and/or a display device, such as a printerand/or a computer monitor.

Further, operation 1106 illustrates recommending at least one of anartificial sensory experience administration schedule. For example, asshown in FIGS. 1 through 5, recommender module 438 may recommend anartificial sensory experience administration schedule. In oneembodiment, recommender module 438 may recommend a time schedule foradministration of a virtual world experience. A time schedule may berecommended by taking into account factors involving the individualand/or the bioactive agent. For example, efficacy of the bioactive agentversus time may be a factor, such as a time period when the bioactiveagent is less effective. Efficacy of the bioactive agent may be a factorin determining when an artificial sensory experience is administeredbecause of the potential for the artificial sensory experience tocompensate for a changed bioactive agent efficacy. An additional factormay include an attribute of the individual, such as how a bioactiveagent and/or specific artificial sensory experience affects theindividual, for example a side effect. Another example of recommendingan artificial sensory experience may be found in Akazawa et al., U.S.Pat. No. 7,155,680, which is incorporated herein by reference. In someinstances, recommender module 438 may include a computer processor.

FIG. 12 illustrates alternative embodiments of the example operationalflow 600 of FIG. 6. FIG. 12 illustrates example embodiments whereoperation 620 may include at least one additional operation. Additionaloperations may include operation 1202, operation 1204, operation 1206,and/or operation 1208.

Operation 1202 illustrates an indication of an unregulated inhalation .For example, as shown in FIGS. 1 through 5, algorithm utilizer module440 may utilize an algorithm for recommending at least one artificialsensory experience. An algorithm for recommending an artificial sensoryexperience may include any computation, formula, statistical survey,and/or look-up table for determining and/or selecting a suitableartificial sensory experience. Some examples may include a computersoftware algorithm, a calculator, a flowchart, and/or a decision tree.In one embodiment, algorithm utilizer module 440 may utilize analgorithm that uses an inputted indication of an analgesic, such asoxycodone, and determines a suitable artificial sensory experience byanalyzing periods of low blood concentration of the oxycodone. In thisembodiment, algorithm utilizer module 440 may recommend an artificialsensory experience that may be effective in pain distraction whenbioactive agent blood concentration may be reduced but before anadditional dose may be available. In some instances, algorithm utilizermodule 440 may include a computer processor.

Further, operation 1204 illustrates an indication of an unregulatedinhalation. For example, as shown in FIGS. 1 through 5, contraindicationalgorithm utilizer module 442 may utilize an algorithm configured foridentifying a contraindication of the artificial sensory experience. Acontraindication of an artificial sensory experience may include givingan indication against the advisability of the artificial sensoryexperience. For example, contraindication algorithm utilizer module 442may utilize an algorithm that considers an individual's personal medicalhistory, such as a phobia, and may recommend not prescribing a certainartificial sensory experience, which may include an object that maytrigger the phobia. Contraindication algorithm utilizer module 442 mayidentify a contraindication of an artificial sensory experience forreasons such as an adverse effect and/or inefficacy. In some instances,contraindication algorithm utilizer module 442 may include a computerprocessor.

Operation 1206 illustrates presenting an indication of an artificialsensory experience at least partly based on a personal medical history.For example, as shown in FIGS. 1 through 5, medical history indicationpresenter module 444 may present an indication of an artificial sensoryexperience at least partly based on a personal medical history. Amedical history may include a personal history and/or a family history.A personal medical history may include a list of previous illnesses,symptoms, medicines, treatments, health risk factors, operations, and/ordoctor visits associated with at least one individual. A personal and/ora family medical history may include life history and/or social historycharacteristics such as smoking, drinking, drug use, sexual history,exercise history, eating history, nutraceutical history, or the like. Inone embodiment, medical history indication presenter module 444 maypresent an indication of a suitable virtual world based on a personalmedical history. In this embodiment, the personal medical history mayindicate that an individual may be averse to a certain virtual world,such as a virtual world with rapid animation that may cause nausea. Insome instances, medical history indication presenter module 444 mayinclude a computer processor and/or a display device, such as a computermonitor and/or a printer.

Operation 1208 illustrates utilizing an algorithm configured forrecommending at least one of an artificial sensory experience. Forexample, as shown in FIGS. 1 through 5, experimental data indicationpresenter module 446 may present an indication of an artificial sensoryexperience at least partly based on experimental data. Experimental datamay include any data from an experiment, such as a clinical trial. Theexperiment may be an experiment including an individual and/or a groupof people. In one embodiment, experimental data indication presentermodule 446 may present an indication of a virtual world suitable for anindividual based on a clinical trial involving a group of 1,000 peopleshowing a certain success rate for reducing a phobia, such as fear ofheights. In some instances, experimental data indication presentermodule 446 may include a computer processor and/or a display device,such as a computer monitor, a mobile phone, and/or a printer.

FIG. 13 illustrates alternative embodiments of the example operationalflow 600 of FIG. 6. FIG. 13 illustrates example embodiments where theoperation 620 may include at least one additional operation. Additionaloperations may include an operation 1302, an operation 1304, anoperation 1306, and/or an operation 1308.

Operation 1302 illustrates presenting at least one of an indication ofan artificial sensory experience or an indication of inhalation therapyat least partly based on a medical reference tool. For example, as shownin FIGS. 1 through 5, reference tool indication presenter module 448 maypresent an indication of an artificial sensory experience at leastpartly based on a medical reference tool. A medical reference tool mayinclude a reference book, a reference database, and/or referencesoftware. Some examples of a medical reference book may include amedical dictionary, a medical journal, and/or a book of druginteractions. One example of a reference database may include theNational Cancer Center Cancer Image Reference (NCC-CIR) database and/orDynaMed. Some examples of reference software may include Skyscapesoftware for a mobile phone and/or MedAlert. In one embodiment,reference tool indication presenter module 448 may present an indicationof an artificial sensory experience based on a reference database, suchas a database including data from a clinical trial. In some instances,reference tool indication presenter module 448 may include a computerprocessor and/or a display device, such as a mobile phone, a printer,and/or a computer monitor.

Operation 1304 illustrates presenting the indication to at least oneoutput device. For example, as shown in FIGS. 1 through 5, output devicepresenter module 450 may present to at least one output device. In oneexample, output device presenter module 450 may present an indication ofa combination prescription medication and an artificial sensoryexperience therapy to an output device 130, such as a printer and/ormonitor at a health clinic. An output device may include any hardwaredevice configured for receiving computer output. Some examples of anoutput device may include a printer, a monitor, a mobile phone, aspeaker, and/or a visual display unit. The output device 130 may be usedby individual 134. In some instances, output device presenter module 450may include a computer processor.

Further, operation 1306 illustrates presenting the indication to atleast one user interface. For example, as shown in FIGS. 1 through 5,user interface presenter module 452 may present to at least one userinterface. In one embodiment, user interface presenter module 452 maypresent to a touchscreen device. A user interface may include means bywhich an individual may interact with a system. Some examples of a userinterface may include a touchscreen, a graphical user interface, atactile interface, and/or a live user interface. In some instances, userinterface presenter module 452 may include a computer processor.

Further, operation 1308 illustrates presenting the indication to atleast one mobile device. For example, as shown in FIGS. 1 through 5,mobile device presenter module 454 may present to at least one mobiledevice. In one embodiment, mobile device presenter module 454 maypresent to a mobile phone. A mobile device may include a portablecomputing device and may have wireless connection capability. Someexamples of a mobile device may include a laptop or notebook computer, apersonal digital assistant (PDA), an ipod, a smartphone, an Enterprisedigital assistant (EDA), and/or a pager. In some instances, mobiledevice presenter module 454 may include a computer processor.

FIG. 14 illustrates alternative embodiments of the example operationalflow 600 of FIG. 6. FIG. 14 illustrates example embodiments whereoperation 620 may include at least one additional operation. Additionaloperations may include operation 1402, operation 1404, and/or operation1406.

Operation 1402 illustrates presenting the indication to at least onethird party. For example, as shown in FIGS. 1 through 5, third partypresenter module 456 may present to an individual's physician. A thirdparty may include a party that is an independent party, person, and/orentity. Some examples of a third party may include a physician, amedical database, a hospital, a law enforcement agency, and/or apharmacy. In one embodiment, third party presenter module 456 maypresent an indication to an insurance company. Another example ofreporting to a third party may include creating displays and reports foraggregating data from therapy results, further discussed in Bair et al.,U.S. Pat. No. 6,067,523, which is incorporated herein by reference. Insome instances, third party presenter module 456 may include a computerprocessor and/or a communications device, such as a monitor and networklink.

Further, operation 1404 illustrates presenting the indication to atleast one health care provider. For example, as shown in FIGS. 1 through5, health care provider presenter module 458 may present to a healthcare provider. A health care provider may include a pharmacy, apharmaceutical company, a medical device company, a researchinstitution, a computer software and/or computer hardware company, awebsite, a nurse and/or a physician. In one embodiment, health careprovider presenter module 458 may present to a physician a prescribedcombination artificial sensory experience and bioactive agent therapyvia a secured website. In some instances, health care provider presentermodule 458 may include a computer processor.

Further, operation 1406 illustrates selectively presenting theindication only to the individual. For example, as shown in FIGS. 1through 5, selective presenter module 460 may selectively present onlyto the individual. Selective presenting may include limiting and/orblocking access of an individual's compliance results and/or aprescribed therapy, such as a prescribed artificial sensory experienceand/or bioactive agent to a specific party. For example, selectivepresenter module 460 may present only to individual 134 and may keepresults of a certain combination therapy confidential. In oneembodiment, an encryption key may be employed to protect selectedinformation. In an additional example, selective presenter module 460may report only to a law enforcement agency and/or representative, suchas a probation officer, and not to individual 134. In some instances,selective presenter module 460 may include a computer processor.

FIG. 15 illustrates alternative embodiments of the example operationalflow 600 of FIG. 6. FIG. 15 illustrates example embodiments where theoperation 620 may include at least one additional operation. Additionaloperations may include an operation 1502.

Operation 1502 illustrates accepting an indication of an individual'sasthma, presenting a prescribed administration schedule of analbuterol-dispensing collar therapy for the individual, and presenting aprescription for engagement of the individual with a virtual worldexperience configured to teach the individual a deep breathingtechnique. For example, as shown in FIGS. 1 through 5, accepter module102 and/or presenter module 104 may accept an indication of analbuterol-dispensing collar configured to be worn proximate to the neckof an individual, accept a prescribed administration schedule of thealbuterot-dispensing collar for the individual, and present aprescription for engagement of the individual with a virtual worldexperience configured to teach the individual a deep breathingtechnique. In some instances, accepter module 102 and/or presentermodule 104 may include a computer processor.

FIG. 16 illustrates a partial view of an example computer programproduct 1600 that includes a computer program 1604 for executing acomputer process on a computing device. An embodiment of the examplecomputer program product 1600 is provided using a signal-bearing mediumbearing 1602, and may include one or more instructions for accepting anindication of at least one health-retated condition and one or moreinstructions for presenting an indication of at least one artificialsensory experience and an indication of at least one inhalation therapyat least partially based on the accepting at least one indication of ahealth-related condition. The one or more instructions may be, forexample, computer executable and/or logic-implemented instructions. Inone implementation, the signal-bearing medium 1602 may include acomputer-readable medium 1606. In one implementation, the signal bearingmedium 1602 may include a recordable medium 1608. In one implementation,the signal bearing medium 1602 may include a communications medium 1610.

FIG. 17 illustrates an example system 1700 in which embodiments may beimplemented. The system 1700 includes a computing system environment.The system 1700 also illustrates the user 118 using a device 1704, whichis optionally shown as being in communication with a computing device1702 by way of an optional coupling 1706. The optional coupling 1706 mayrepresent a local, wide-area, or peer-to-peer network, or may representa bus that is internal to a computing device (e.g., in exampleembodiments in which the computing device 1702 is contained in whole orin part within the device 1704). A storage medium 1708 may be anycomputer storage media.

The computing device 1702 includes computer-executable instructions 1710that when executed on the computing device 1702 cause the computingdevice 1702 to accept an indication of a schedule for administration ofa bioactive agent to an individual and present an indication of anartificial sensory experience at least partly based on the accepting anindication of the schedule for administration of the bioactive agent tothe individual. As referenced above and as shown in FIG. 17, in someexamples, the computing device 1702 may optionally be contained in wholeor in part within the device 1704.

In FIG. 17, then, the system 1700 includes at least one computing device(e.g., 1702 and/or 1704). The computer-executable instructions 1710 maybe executed on one or more of the at least one computing device. Forexample, the computing device 1702 may implement the computer-executableinstructions 1710 and output a result to (and/or receive data from) thecomputing device 1704. Since the computing device 1702 may be wholly orpartially contained within the computing device 1704, the device 1704also may be said to execute some or all of the computer-executableinstructions 1710, in order to be caused to perform or implement, forexample, various ones of the techniques described herein, or othertechniques.

The device 1704 may include, for example, a portable computing device,workstation, or desktop computing device. In another example embodiment,the computing device 1702 is operable to communicate with the device1704 associated with the user 118 to receive information about the inputfrom the user 118 for performing data access and data processing andpresenting an output of the user-health test function at least partlybased on the user data.

FIG. 18 illustrates system 1800 for monitoring at least one healthattribute of an individual during an artificial sensory experience,associating a characteristic of the artificial sensory experience withthe at least one health attribute of the individual, and/or modifying atleast one of an inhalation device-dispensed bioactive agent or theartificial sensory experience at least partially based on associating acharacteristic of the artificial sensory experience with the at leastone health attribute of the individual. System 1800 may includemonitorer module 2002, associater module 2016, modifier module 2030,and/or administration unit 106. Administration unit 106 may includephysical intervention effector module 108 and/or artificial sensoryexperience effector module 120. Physical intervention effector module108 may include inhalation device 110. Inhalation device 110 may includeinhalation collar 112 and/or virtual reality headset 114. Additionally,system 1800 may include mobile device 132.

FIG. 19 illustrates system 1800 for monitoring at least one healthattribute of an individual during an artificial sensory experience,associating a characteristic of the artificial sensory experience withthe at least one health attribute of the individual, and/or modifying atleast one of an inhalation device-dispensed bioactive agent or theartificial sensory experience at least partially based on associating acharacteristic of the artificial sensory experience with the at leastone health attribute of the individual. System 1800 may includemonitorer module 2002, associater module 2016, modifier module 2030,accepter module 102, administration unit 106, and/or monitoring unit3202. Accepter module 102 may receive and/or transmit information and/ordata to and/or from user 118, database 122, side effect monitorpresenter module 2028, output device 130, and/or health care provider136. A user may include user 118, individual 134, health care provider136, a patient, and/or another affected person or entity. Database 122may include medication database 124 and/or artificial sensory experiencedatabase 126. Monitoring unit 3202 may monitor individual 134 and mayinclude drug sensing unit 3204, physiologic activity monitor 3206, brainactivity measurement unit 3208, behavior monitor 3210, instrumentationmonitor 3212, compliance reporting unit 3214, voice response module3216, hearing test module 3218, and/or scale 3220. Administration unit106 may include physical intervention effector module 108 and/orartificial sensory experience effector module 120. Physical interventioneffector module 108 may include inhalation device 110. Inhalation device110 may include inhalation collar 112 and/or virtual reality headset114. Additionally, mobile device 132 may communicate with acceptermodule 102, presenter module 104, monitorer module 2002, associatermodule 2016, modifier module 2030, healthcare provider 136, user 118,individual 134, monitoring unit 3202, and/or administration unit 106.

FIG. 20 further illustrates system 1800 including monitorer module 2002,associater module 2016, and/or modifier module 2030. Monitorer module2002 may include data receiver module 2004, health attribute monitorermodule 2006, neurophysiological monitorer module 2008, recorder module2012, and/or observer module 2014. Neurophysiological monitorer module2008 may include neurophysiological measurer module 2010. Associatermodule 2016 may include physiological response associater module 2018,report accepter module 2024, utilizer module 2026, and/or comparermodule 2028. Physiological response associater module 2018 may includeartificial sensory experience associater module 2020 and/or healthattribute associater module 2022.

FIG. 21 further illustrates system 1800 including monitorer module 2002,associater module 2016, and/or modifier module 2030. Modifier module2030 may include access modifier module 2032, visual object modifiermodule 2038, sound alterer module 2044, efficacy modifier module 2052,side effect modifier module 2054, adder module 2056, deleter module2058, sensate modifier module 2060, mobile device modifier module 2064,dosage modifier module 2066, bioactive agent modifier module 2068,and/or delivery modifier module 2070. Access modifier module 2032 mayinclude restricter module 2034 and/or granter module 2036. Visual objectmodifier module 2038 may include color scheme modifier module 2040and/or text modifier module 2042. Sound alterer module 2044 may includemusic alterer module 2046, ambient noise alterer module 2048, and/orvoice alterer module 2050. Sensate modifier module 2060 may includestimulus modifier module 2062.

System 1800 generally represents instrumentality for monitoring at leastone health attribute of an individual during an artificial sensoryexperience, associating a characteristic of the artificial sensoryexperience with the at least one health attribute of the individual, andmodifying at least one of an inhalation device-dispensed bioactive agentor the artificial sensory experience at least partially based onassociating a characteristic of the artificial sensory experience withthe at least one health attribute of the individual. The operations ofmonitoring at least one health attribute of an individual during anartificial sensory experience, associating a characteristic of theartificial sensory experience with the at least one health attribute ofthe individual, and modifying at least one of an inhalationdevice-dispensed bioactive agent or the artificial sensory experience atleast partially based on associating a characteristic of the artificialsensory experience with the at least one health attribute of theindividual may be accomplished electronically, such as with a set ofinterconnected electrical components, an integrated circuit, and/or acomputer processor.

FIG. 22 illustrates an operational flow 2200 representing exampleoperations related to monitoring at least one health attribute of anindividual during an artificial sensory experience, associating acharacteristic of the artificial sensory experience with the at leastone health attribute of the individual, and modifying at least one of aninhalation device-dispensed bioactive agent or the artificial sensoryexperience at least partially based on associating a characteristic ofthe artificial sensory experience with the at least one health attributeof the individual. In FIG. 22 and in following figures that includevarious examples of operational flows, discussion and explanation may beprovided with respect to the above-described examples of FIGS. 18through 21, and/or with respect to other examples and contexts. However,it should be understood that the operational flows may be executed in anumber of other environments and contexts, and/or in modified versionsof FIGS. 18 through 21. Also, although the various operational flows arepresented in the sequence(s) illustrated, it should be understood thatthe various operations may be performed in other orders than those whichare illustrated, or may be performed concurrently.

After a start operation, the operational flow 2200 moves to operation2210. Operation 2210 depicts monitoring at least one health attribute ofan individual during an artificial sensory experience. For example, asshown in FIGS. 18 through 21, monitorer module 2002 may monitor at leastone health attribute of an individual during an artificial sensoryexperience. In one embodiment, monitorer module 2002 may monitor a heartrate while an individual experiences a virtual world. In thisembodiment, monitoring the heart rate may enable a health care providerto closely observe the patient and offer quality care. Monitoring mayinclude, for example, observing, recording, detecting, comparing, and/oran ongoing process of collecting and/or analyzing information. A healthattribute may include a characterisitic and/or a quality associated withan individual's physical, mental, and/or social well-being. Someexamples of a health attribute may include blood pressure, body weight,heart rate, diet, stress level, body temperature, and/or respiratoryrate. Other examples of a health attribute may include pupil size, bloodglucose amount, a pain scale measurement, speech pitch modulation,and/or facial expression. One example of monitoring a health attributemay be found in Xueliang, H. et al., A Wireless PharmaceuticalCompliance Monitoring System Based on Magneto-Inductive Sensors, SENSORSJOURNAL, IEEE, 7(12):1711-19 (2007), which is incorporated herein byreference. In some instances, monitorer module 2002 may include acomputer processor and/or medical instrumentation, such as anelectrocardiograph.

In another embodiment, monitorer module 2002 may remotely monitor aheart rate while an individual experiences a virtual world. One exampleof remote monitoring may include a sensor configured to send a signal toa receiver. Other examples of remote monitoring may be found in McGrath,U.S. Pat. No. 7,272,431; Matthews et al., U.S. Pat. No. 7,245,956; Clarket al., U.S. Patent Publication No. 2006/0058694; Harland, C. J. et al.,Electric Potential Probes-New Directions in the Remote Sensing of theHuman Body, MEAS. SCI. TECHNOL. 13: 163-169 (2002); Harland, C. J etal., Remote detection of human electroencephalograms using ultrahighinput impedance electric potential sensors, APPL. PHYS. LETT., 81(17)3284-3286 (2002); and/or McGrath, U.S. Patent Publication No.2008/0045832, each of which are incorporated herein by reference. In aseparate embodiment, monitorer module 2002 may non-invasively monitorpupil size while an individual experiences a virtual world. Someexamples of non-invasive monitoring may include Prance, R. J. et al.,Adaptive Electric Potential Sensors for smart signal acquisition andprocessing, 2007 Journal of Physics: Conference Series, 76: 012025;Harland, C. J. et al., High resolution ambulatory electrocardiographicmonitoring using wrist-mounted electric potential sensors, MEAS. SCI.TECHNOL., 14:923-928 (2003); and Abourizk, et al., U.S. Pat. No.7,226,164, each of which are incorporated herein by reference.

Then, operation 2220 depicts associating a characteristic of theartificial sensory experience with the at least one health attribute ofthe individual. For example, as shown in FIGS. 18 through 21, associatermodule 2016 may associate a characteristic of the artificial sensoryexperience with the at least one health attribute of the individual. Inone embodiment, associater module 2016 may associate a characteristic ofthe artificial sensory experience, such as soothing background music,with a health attribute of an individual, such as a heart rate. Someexamples of an artificial sensory experience characteristic may includemusic, lighting, a color scheme, and/or action in the artificial sensoryexperience, such as movement and/or simulated fighting in a virtualworld gaming environment (World of Warcraft). Associating may include,for example, relating, statistically correlating, and/or linkinginformation and/or data. One further example of associating may be foundin Davies, et al., U.S. Patent Publication No. 2008/0212847, which isincorporated herein by reference. In some instances, associater module2016 may include a computer processor.

Then, operation 2230 depicts modifying at least one of an inhalationdevice-dispensed bioactive agent or the artificial sensory experience atleast partially based on associating a characteristic of the artificialsensory experience with the at least one health attribute of theindividual. For example, as shown in FIGS. 18 through 21, modifiermodule 2030 may modify at least one of an inhalation device-dispensedbioactive agent or the artificial sensory experience at least partlybased on associating a characteristic of the artificial sensoryexperience with the at least one health attribute of the individual. Oneexample of an inhalation device configured to dispense a bioactive agentmay include an inhaler used for delivering a bioactive agent into thebody using a body airway. Some other examples may include a collar,necklace, and/or a bracelet with a bioactive agent dispenser proximateto the nose, mouth, and/or inhalation route. In one embodiment, modifiermodule 2030 may modify an inhaled steroid by decreasing a dosagesubsequent based on associating an individual's ease of breathing with amountainous virtual world. In this embodiment, the mountainous virtualworld may serve to lessen an individual's elevated anxiety and mayencourage a peaceful and/or relaxing atmosphere, which may be indicatedby the eased and/or relaxed breathing. In another embodiment, modifiermodule 2030 may decrease an inhaled antidepressant dosage based on anindividual's decreased blood pressure while experiencing a virtual worldconfigured to facilitate a happy environment. In this embodiment, thedecreased blood pressure and the virtual world may be designed to reducedepression and may warrant a modification of a medication, such as adecreased inhaled antidepressant dosage. Some examples of an artificialsensory experience may include a virtual experience, such as an onlinegame or a social networking site, and/or a real-world sensory stimulus,such as a smell and/or a sight. Other examples of modifying anartificial sensory experience may include changing a computer gameand/or changing a computer display background. An additional example ofmodifying an artificial sensory experience may include a changing avirtual game utilizing a neuroheadset having sensors for detectingmental states based on, for example, electrical signals and/or bloodflow in the brain. See, for example, headsets manufactured by EmotivSystems, Inc. In some instances, modifier module 2030 may include acomputer processor.

FIG. 23 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 23 illustrates example embodiments whereoperation 2210 may include at least one additional operation. Additionaloperations may include operation 2302, and/or operation 2304.

Operation 2302 illustrates receiving data from an automated medicaldevice. For example, as shown in FIGS. 18 through 21, data receivermodule 2004 may receive data from an automated medical device, such asan electrocardiograph. An automated medical device may include a medicalmonitor and/or a device that senses a patient's vital signs andcommunicates the results, such as to a monitor and/or a user 118. Someexamples of an automated medical device may include anelectrocardiograph, such as a Holter monitor, medical imaging machines,such as an ultrasound machine and/or a magnetic resonance imagingmachine, analysis instrumentation, such as a blood glucose meter, and/ora pulse oximeter. Other examples of an automated medical device mayinclude a pedometer, a heart rate monitor, a blood pressure monitor, abody-fat analyzer, and/or a neurophysiological monitor. Additionally, amulti-parameter automated medical device may simultaneously measureand/or track multiple vital signs. One example of an automated devicemay include a tele-medicine application, further described inJeanpierre, L. et al., Automated medical diagnosis with fuzzy stochasticmodels: monitoring chronic diseases, ACTA BIOTHERETICA, 52(4):291-311(2004), which is incorporated herein by reference. In some instances,data receiver module 2004 may include a computer processor, a monitorcoupled to a computer processor, and/or other medical devices, such asthose described above.

Operation 2304 illustrates monitoring at least one of physical activity,body weight, body mass index number, heart rate, blood oxygen level, orblood pressure temporally associated with an artificial sensoryexperience. For example, as shown in FIGS. 18 through 21, healthattribute monitorer module 2006 may monitor an individual's heart rate.Physical activity may include any form of exercise, movement, and/orbodily activity. Some examples of a physical activity may includeexercise, body movement, walking, running, and/or muscle stretching.Monitoring physical activity may include using a pedometer, anaccelerometer, for example, available from New-Lifestyles, Inc., Lee'sSummit, Mo., and/or other devices, such as actometers, further discussedin Zhang et al., Measurement of Human Daily Physical Activity, OBESITYRESEARCH, 11(1):33-40 (2003), which is incorporated herein by reference.

Monitoring a body weight and/or a body mass index may include using ascale and/or a computing device. In one embodiment, health attributemonitorer module 2006 may monitor a body mass index of an individualexperiencing a Wii Fitness game while being administered a weight lossmedication by using a scale 3220 coupled with a computer processor. Inthe same embodiment, scale 3220 and computer processor may constantlymonitor the body mass index of the individual 134. Further, monitoring aheart rate may include measuring work done by the heart, such asmeasuring beats per unit time and/or a pulse. Monitoring a blood oxygenlevel may include utilizing a pulse oximeter and/or measuring oxygensaturation directly through a blood sample. Monitoring blood pressuremay include utilizing a sphygmomanometer, which may be coupled to acomputer processor or other monitoring device. Monitoring physicalactivity, a heart rate, a blood oxygen level, and/or blood pressure whenan individual is experiencing an artificial sensory experience may serveto determine the efficacy of a bioactive agent. For example, when anantianxiety medication is administered to an individual prior to and/orduring an artificial sensory experience, such as a spider world designedto overcome a spider phobia, health attribute monitorer module 2006 maymonitor a heart rate in order to determine whether the antianxietymedication is effective. In the above example, the individual's heartrate may decrease due to a decrease in anxiety as the antianxietymedication takes effect, which may indicate drug efficacy. Additionally,health attribute monitorer module 2006 may monitor before, during,and/or after an individual experiences an artificial sensory experience.In some instances, health attribute monitorer module 2006 may include acomputer processor and/or other medical instrumentation, such as thatdiscussed herein.

FIG. 24 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 24 illustrates example embodiments whereoperation 2210 may include at least one additional operation. Additionaloperations may include operation 2402, and/or operation 2404.

Operation 2402 illustrates monitoring a neurophysiological activity. Forexample, as shown in FIGS. 18 through 21, neurophysiological monitorermodule 2008 may monitor a neurophysiological measurement, such as, forexample, a measurement of the activation signal of muscles(electromyography) and/or the measurement of transcranial magneticstimulation. A neurophysiological measurement may include a measurementof the brain, nervous system, and/or neuromonitoring. In some instances,neurophysiological activity monitorer module 3408 may include a computerprocessor and/or a medical device, such as device configured to measuresomatosensory evoked potentials (SSEPs), auditory brainstem response(ABR), and/or scalp sensors used in electroencephalography (EEG). Insome instances, neurophysiological monitorer module 2008 may include acomputer processor and/or medical instrumentation.

Further, operation 2404 illustrates measuring at least one physiologicactivity using at least one of electroencephalography, computed axialtomography, positron emission tomography, magnetic resonance imaging,functional magnetic resonance imaging, functional near-infrared imaging,or magnetoencephalography. For example, as shown in FIGS. 18 through 21,neurophysiological measurer module 2010 may measure at least onephysiologic activity using at least one of electroencephalography,computed axial tomography, positron emission tomography, magneticresonance imaging, functional magnetic resonance imaging, functionalnear-infrared imaging, or magnetoencephalography. In some instances,neurophysiological measurer module 2010 may include a computerprocessor, and/or a medical device, such as an apparatus configured toperform a computed axial tomography scan.

Electroencephalography may include measuring the electrical activity ofthe brain by recording from electrodes placed on the scalp or, inspecial cases, subdurally, or in the cerebral cortex. The resultingtraces are known as an electroencephalogram (EEG) and represent asummation of post-synaptic potentials from a large number of neurons.EEG is most sensitive to a particular set of post-synaptic potentials:those which are generated in superficial layers of the cortex, on thecrests of gyri directly abutting the skull and radial to the skull.Dendrites that are deeper in the cortex, inside sulci, are in midline ordeep structures (such as the cingulate gyrus or hippocampus) or thatproduce currents that are tangential to the skull make a smallercontribution to the EEG signal.

One application of EEG is event-related potential (ERP) analysis. An ERPis any measured brain response that is directly the result of a thoughtor perception. ERPs can be reliably measured usingelectroencephalography (EEG), a procedure that measures electricalactivity of the brain, typically through the skull and scalp. As the EEGreflects thousands of simultaneously ongoing brain processes, the brainresponse to a certain stimulus or event of interest is usually notvisible in the EEG. One of the most robust features of the ERP responseis a response to unpredictable stimuli. This response is known as theP300 (P3) and manifests as a positive deflection in voltageapproximately 300 milliseconds after the stimulus is presented.

A two-channel wireless brain wave monitoring system powered by athermo-electric generator has been developed by IMEC (InteruniversityMicroelectronics Centre, Leuven, Belgium). This device uses the bodyheat dissipated naturally from the forehead as a means to generate itselectrical power. The wearable EEG system operates autonomously with noneed to change or recharge batteries. The EEG monitor prototype iswearable and integrated into a headband where it consumes 0.8milliwatts. A digital signal processing block encodes extracted EEGdata, which is sent to a PC via a 2.4-GHz wireless radio link. Thethermoelectric generator is mounted on the forehead and converts theheat flow between the skin and air into electrical power. The generatoris composed of 10 thermoelectric units interconnected in a flexible way.At room temperature, the generated power is about 2 to 2.5-mW or 0.03-mWper square centimeter, which is the theoretical limit of powergeneration from the human skin. Such a device is proposed to associateemotion with EEG signals. See Clarke, “IMEC has a brain wave: feed EEGemotion back into games,” EE Times online,http://www.eetimes.eu/design/202801063 (Nov. 1, 2007).

Computed axial tomography may include medical imaging employingtomography and digital geometry processing for generating athree-dimensional image of the inside of an object from a large seriesof two-dimensional X-ray images taken around a single axis of rotation.Positron emission tomography may include a nuclear medicine imagingtechnique, which produces a three-dimensional image and/or map of atleast one functional process in the body. The system detects pairs ofgamma rays emitted indirectly by a positron-emitting radionuclide (atracer), which is introduced into the body on a biologically activemolecule. Images of tracer concentration in 3-dimensional space withinthe body may then be reconstructed by computer analysis. Magneticresonance imaging may include a medical imaging technique using amagnetic field to align the nuclear magnetization of hydrogen atoms inwater in the body, resulting in an image of the body. Functionalmagnetic resonance imaging may include and imaging method for measuringhaemodynamic response related to neural activity in the brain or spinalcord. Functional near-infrared imaging (fNIR) may include aspectroscopic neuro-imaging method for measuring the level of neuronalactivity in the brain. Functional near-infrared imaging (fNIR) is basedon neuro-vascular coupling, or the relationship between metabolicactivity and oxygen level (oxygenated hemoglobin) in feeding bloodvessels.

Magnetoencephalography includes measuring the magnetic fields producedby electrical activity in the brain using magnetometers such assuperconducting quantum interference devices (SQUIDs) or other devices.Smaller magnetometers are in development, including a mini-magnetometerthat uses a single milliwatt infrared laser to excite rubidium in thecontext of an applied perpendicular magnetic field. The amount of laserlight absorbed by the rubidium atoms varies predictably with themagnetic field, providing a reference scale for measuring the field. Thestronger the magnetic field, the more light is absorbed. Such a systemis currently sensitive to the 70 fT range, and is expected to increasein sensitivity to the 10 fT range. See Physorg.com, “New mini-sensor mayhave biomedical and security applications,” Nov. 1, 2007,http://www.physorg.com/news13151078.html, which is incorporated hereinby reference.

FIG. 25 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 25 illustrates example embodiments whereoperation 2210 may include at least one additional operation. Additionaloperations may include operation 2502, and/or operation 2504.

Operation 2502 illustrates recording at least one monitored healthattribute of the individual. For example, as shown in FIGS. 18 through21, recorder module 2012 may record at least one monitored healthattribute of the individual. Recording a monitored health attribute mayinclude capturing data, including the monitored health attribute, to arecord and/or a format stored on a storage medium. In one embodiment,recorder module 2012 may record a monitored heart rate onto a hard diskdrive. Other examples of a record and/or storage medium may includeflash memory devices, a tape drive, circuitry with non-volatile and/orvolatile RAM, an optical disc, for example a CD and/or DVD, and/or apaper record, such as a collection of printed spreadsheets and/or otherlists of data. In an additional embodiment, recorder module 2012 mayrecord a monitored health attribute by utilizing data acquisitionsoftware. Further discussion of data acquisition may be found in Green,T. et al., PC-Based Medical Data Acquisition and Analysis, cbms, p.0159, EIGHTH IEEE SYMPOSIUM ON COMPUTER-BASED MEDICAL SYSTEMS (CBMS'95),1995, which is incorporated herein by reference. In some instances,recorder module 2012 may include a computer processor and/or other datalogging instrumentation, such as NI CompactDAQ hardware, available fromNational Instruments, Austin, Tex.(http://www.ni.com/dataacquisition/compactdaq/).

Operation 2504 illustrates observing at least one indication of anexpected behavior pattern proximate in time to a characteristic of theartificial sensory experience. For example, as shown in FIGS. 18 through21, observer module 2014 may observe at least one indication of anexpected behavior pattern proximate in time to a characteristic of theartificial sensory experience. In one embodiment, observer module 2014may observe an elevated respiratory rate and increased sweatingproximate in time to an individual experiencing an elevated height in avirtual world designed to help the individual overcome acrophobia, or aphobia of heights. Observing an indication of an expected behaviorpattern proximate in time to an artificial sensory experiencecharacteristic may indicate a likelihood of causality by the artificialsensory experience characteristic on the expected behavior pattern. Insome instances, observer module 2014 may include a computer processorand/or medical instrumentation, such as heart rate monitor coupled to acomputer processor configured to statistically link and/or correlateinformation.

FIG. 26 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 26 illustrates example embodiments whereoperation 2220 may include at least one additional operation. Additionaloperations may include operation 2602, operation 2604, and/or operation2606.

Operation 2602 illustrates associating a characteristic of theartificial sensory experience with at least one physiological responseof the individual. For example, as shown in FIGS. 18 through 21,physiological response associater module 2018 may associate acharacteristic of the artificial sensory experience with at least onephysiological response of the individual. In one embodiment,physiological response associater module 2018 may associate soothingmusic in an artificial sensory experience with an individual's Loweredblood pressure and reduced sweating. In this embodiment, associating anartificial sensory experience characteristic with a physiologicalresponse may serve to enable a health care professional to better meetthe needs of the individual. In some instances, physiological responseassociater module 2018 may include a computer processor.

Further, operation 2604 illustrates associating at Least one of anobject, an action, an avatar, or an environment of the artificialsensory experience with at least one physiological response of theindividual. For example, as shown in FIGS. 18 through 21, artificialsensory experience associater module 2020 may associate at least one ofan object, an action, an avatar, or an environment of the artificialsensory experience with at least one physiological response of theindividual. In one embodiment, artificial sensory experience associatermodule 2020 may associate an artificial sensory experience environmentwith an individual's pulse. Some examples of an object of an artificialsensory experience may include a background, associated music, and/or avisual observation, such as a landscape. Some examples of an action mayinclude an action by an avatar, an action by a virtual game, such as alevel advancement, and/or an action which may prompt the user to act,such as a textual based set of questions. An avatar may include agraphical representation of a character. Some examples of an artificialsensory experience environment may include a landscape and/or acircumstance in which the individual and/or an avatar controlled by theindividual may be placed. In some instances, artificial sensoryexperience associater module 2020 may include a computer processor.

Further, operation 2606 illustrates associating a characteristic of theartificial sensory experience with at least one of blood pressure,pulse, pupil dilation, respiration rate, skin response, or voiceresponse of the individual. For example, as shown in FIGS. 18 through21, health attribute associater module 2022 may associate acharacteristic of the artificial sensory experience with at Least one ofblood pressure, pulse, pupil dilation, respiration rate, skin response,or voice response of the individual. In one embodiment, health attributeassociater module 2022 may associate a set of avatar interactions in avirtual world with a skin response, such as increased sweating, of anindividual. Such an association may allow a health care provider tomodify a therapy, for example increase an antianxiety medication. Inanother embodiment, health attribute associater module 2022 mayassociate a lighting scheme in a virtual world with an increased pulsein an individual. In this embodiment, increased pulse may indicate adecrease in depression and may indicate to a health care professional amedication adjustment may be needed. A change and/or a certainmeasurement of blood pressure, pulse, pupil dilation, respiration rate,skin response, and/or voice response may indicate a modification of anartificial sensory experience and/or a bioactive agent may be neededand/or desired. In some instances, health attribute associater module2022 may include a computer processor.

FIG. 27 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 27 illustrates example embodiments whereoperation 2220 may include at least one additional operation. Additionaloperations may include operation 2702, operation 2704, and/or operation2706.

Operation 2702 illustrates accepting a report from the individual of anassociation of a characteristic of the artificial sensory experience andthe at least one health attribute. For example, as shown in FIGS. 18through 21, report accepter module 2024 may accept a report from theindividual of an association of a characteristic of the artificialsensory experience and the at least one health attribute. In oneembodiment, report accepter module 2024 may accept a self evaluationfrom an individual of an amount of breathing difficulty that theindividual feels when experiencing an artificial sensory experience,such as an online game (Second Life). In this embodiment, breathingdifficulty may indicate stress. A report from an individual may includeany type of input from the individual. One example of a report from anindividual may include a self evaluation, such as an evaluation of howmuch pain the individual is experiencing. Another example of a reportfrom an individual may be found in Chikovani, et al., U.S. Pat. No.6,383,135, which is incorporated herein by reference. In some instances,report accepter module 2024 may include a computer processor.

Operation 2704 illustrates utilizing an algorithm configured tocorrelate an artificial sensory experience characteristic with at leastone health attribute. For example, as shown in FIGS. 18 through 21,utilizer module 2026 may utilize an algorithm configured to correlate anartificial sensory experience characteristic with at least one healthattribute. In one embodiment, utilizer module 2026 may utilize analgorithm for correlating a length of a virtual experience designed toreduce stress and an amount of stress felt by the individual, where theindividual may input a result from a self evaluation. A further exampleof utilizing an algorithm may be found in Kurtberg, et al., U.S. Pat.No. 6,487,520, which is incorporated herein by reference. In someinstances, utilizer module 2026 may include a computer processor.

Operation 2706 illustrates comparing current measured behavior withexpected behavior data that is correlated with an artificial sensoryexperience. For example, as shown in FIGS. 18 through 21, comparermodule 2028 may compare current measured behavior with expected behaviordata that is correlated with an artificial sensory experience. In oneembodiment, comparer module 2028 may compare an individual's respiratoryrate when experiencing an artificial sensory experience and a databaseincluding information regarding an expected respiratory rate correlatedwith at least a similar artificial sensory experience. Comparing currentmeasured behavior with expected behavior data correlated with anartificial sensory experience may be beneficial, for example, whendetermining if an individual is responding normally or abnormally to anartificial sensory experience. By comparing current behavior with pastbehavior, a health professional may be able to determine the efficacy ofan artificial sensory experience and/or a bioactive agent therapy. Insome instances, comparer module 2028 may include a computer processor.

FIG. 28 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 28 illustrates example embodiments whereoperation 2230 may include at least one additional operation. Additionaloperations may include operation 2802, operation 2804, and/or operation2806.

Operation 2802 illustrates modifying access to at least a portion of theartificial sensory experience. For example, as shown in FIGS. 18 through21, access modifier module 2032 may modify access to a portion of theartificial sensory experience, for example to alter at least one effectof the bioactive agent. In one instance, access modifier module 2032 maymodify access to a portion of an artificial sensory experience includinga photo gallery portion of a social networking website. Such modifiedaccess may, for example white being administered an antidepressant,function therapeutically to prevent access of an individual topotentially depressing, stressful, or otherwise triggering sensoryexperiences, and/or the modified access may involve presentation of asensory experience that affirmatively improves a condition (e.g., brightsunny images for a clinically depressed individual). In some instances,access modifier module 2032 may include a computer processor.

Further, operation 2804 illustrates restricting access to at least aportion of the artificial sensory experience. For example, as shown inFIGS. 18 through 21, restricter module 2034 may restrict access to atleast a portion of the artificial sensory experience. In one instance,restricter module 2034 may restrict access to a portion of a virtualworld designed to overcome a flying phobia, where access to a portion ofa simulated flying experience is prevented, for example, a jet take-offportion. In this instance, the most stressful portion of the flightsimulation may be avoided. In some instances, restricter module 2034 mayinclude a computer processor.

Further, operation 2806 illustrates granting access to at least aportion of the artificial sensory experience. For example, as shown inFIGS. 18 through 21, granter module 2036 may grant access to at least aportion of the artificial sensory experience. In one instance andcontinuing with the above example, granter module 2036 may grant accessto at least a portion of a virtual world designed to overcome a flyingphobia, where access to a portion of a simulated flying experience isgranted, including a jet landing portion. Such a simulation presentinggradually increasing contact with the object of the fear may serve toprovide conditioning for the individual to eventually overcome thephobia. In some instances, granter module 2036 may include a computerprocessor.

FIG. 29 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 29 illustrates example embodiments whereoperation 2230 may include at least one additional operation. Additionaloperations may include operation 2902, operation 2904, and/or operation2906.

Operation 2902 illustrates modifying visible content in an artificialsensory experience to alter at least one effect of the bioactive agent.For example, as shown in FIGS. 18 through 21, visual object modifiermodule 2038 may modify visible content in an artificial sensoryexperience to alter at least one effect of the bioactive agent. In oneinstance and continuing with the above example, visual object modifiermodule 2038 may modify a visual object, such as adding window coversover the windows of a virtual plane in a virtual world designed toovercome a flying phobia to alter at least one effect of an anti-anxietymedication. In this example, the window covers may reduce anxietyexperienced by the individual in addition to anxiety reduction mediatedby the anti-anxiety medication. Additional examples of visible contentand/or a visual object may include a virtual character (i.e., anavatar), an action performed by the avatar, and/or character attributeand/or artifact, such as facial features, weapons, clothing, a sky,and/or tools. In some instances, visual object modifier module 2038 mayinclude a computer processor.

Further, operation 2904 illustrates modifying a color scheme of anartificial sensory experience to alter at least one effect of thebioactive agent. For example, as shown in FIGS. 18 through 21, colorscheme modifier module 2040 may modify a color scheme of an artificialsensory experience to alter at least one effect of the bioactive agent.In one instance, color scheme modifier module 2040 may modify a colorscheme by adding brighter background lights and colors in a virtualworld designed to overcome depression to alter an effect of an inhaledanti-depression medication. Such a color scheme modification may help toovercome depression, seasonal affective disorder, and/or other disordersbecause it has been purported that color and/or light may affectnonvisual psychological processes. Discussion regarding the effects ofcolor and/or light on nonvisual psychological processes may be found inKnez, Effects of colour of light on nonvisual psychological processes,JOURNAL OF ENVIRONMENTAL PSYCHOLOGY, 21(2):201-208 (2001); M. R BassoJr., Neurobiological relationships between ambient lighting and thestartle response to acoustic stress in humans, INT J NEUROSCI.,110(3-4):147-57 (2001), and Lam et al., The Can-SAD Study: a randomizedcontrolled trial of the effectiveness of light therapy and fluoxetine inpatients with winter seasonal affective disorder, AMERICAN JOURNAL OFPSYCHIATRY, 163(5):805-12 (2006), each incorporated by reference. Insome instances, color scheme modifier module 2040 may include a computerprocessor.

Further, operation 2906 illustrates modifying at least a portion of textof an artificial sensory experience to alter at least one effect of thebioactive agent. For example, as shown in FIGS. 18 through 21, textmodifier module 2042 may modify at least a portion of text of anartificial sensory experience to alter at least one effect of thebioactive agent. In one instance, text modifier module 2042 may modify aportion of instructional text in a virtual world, such as a computergame, to alter an effect of a bioactive agent, such as anaromatherapeutic for stress relief. In this instance, text modificationmay include changing the text font and/or style (e.g., size type, and/orcolor). Additionally, text modification may improve memory by utilizingtechniques such as underlining, highlighting, boldfacing, and/ormnemonics as discussed in Carney, R. N., & Levin, J. R., Mnemonicinstruction with a focus on transfer, JOURNAL OF EDUCATIONAL PSYCHOLOGY,92(4):783-90, incorporated herein by reference. Another example mayinclude instructional text providing contextual or associativeinformation, perhaps individualized, to aid in remembering during therest of a module. Another example of text modification and memory mayinclude modifying the use of interactive components, e.g. via a keyboardand/or speakers, to use multiple forms of memory input, includingvisual, auditory, motor, and contextual. For example, this may be usedto aid memory and/or in learning disorders such as dysgraphia, and/ormemory disorders, such as in conjunction with memory-enhancingmedications, for example cholinesterase inhibitors or herbal memorysupplements. Additionally, text messages may be added and/or alteredbased on cognitive therapy but individualized for the person,affliction, and/or medication (e.g. an antidepressant and instructionsto work toward a goal within a game that will aid in refuting automaticnegative thoughts). In some instances, text modifier module 2042 mayinclude a computer processor.

FIG. 30 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 30 illustrates example embodiments whereoperation 2230 may include at least one additional operation. Additionaloperations may include operation 3002, operation 3004, and/or operation3006.

Operation 3002 illustrates altering audible content in an artificialsensory experience. For example, as shown in FIGS. 18 through 21, soundalterer module 2044 may alter audible content in an artificial sensoryexperience. In one instance, sound alterer module 2044 may alter a soundin a virtual world, such as an instructor's voice tone in aninstructional tutorial. This may be done as a custom-tailored feature.For example, various voice tones may be tested with an individual inorder to find one that has the most significant benefit for theindividual, in conjunction with an inhaled bioactive agent. In someinstances, sound alterer module 2044 may include a computer processor.

Further, operation 3004 illustrates altering at least a portion of musicin the artificial sensory experience. For example, as shown in FIGS. 18through 21, music alterer module 2046 may alter at least a portion ofmusic in the artificial sensory experience. In one instance, musicalterer module 2046 may alter a portion of music including backgroundmusic in an instructional tutorial. Music in the artificial sensoryexperience may include pitch, rhythm, tempo, meter, and articulation,dynamics, lyrics, timbre and texture. In one specific instance, musicalterer module 2046 may alter a portion of uptempo music to soothingclassical music in an artificial sensory experience coupled withadministration of an anxiolytic. Such a music alteration may serve toprovide a calming and/or relaxing environment where the effects of theanxiolytic may be facilitated. In another instance, a sound pitch may bealtered to affect bone (as in healing fractures and/or promoting bonegrowth) and/or sinuses (including joints). Additionally, music alterermodule 2046 may include providing another type of sound, such as a lowfrequency, to aid in heating, e.g. in conjunction with pain medicationand/or an anti-inflammatory medication. In another example, the soundmay originate from a natural source, for instance a purr of a cat,possibly provided at a particular pitch, to aid in relaxation, as inconjunction with a tranquilizer, and/or in healing tissue in conjunctionwith pain medication or anti-inflammatories. Further discussionregarding low frequency therapeutic biomechanical stimulation may befound in von Muggenthaler, E. K., The Felid purr: low frequencytherapeutic biomechanical stimulation, 12th International Conference onLow Frequency Noise and Vibration and its Control, Bristol, UK, Sep.18-20, 2006, Abstract located at Fauna Communications Research Institute<http://animalvoice.com/catpurrP.htm#2pAB7.%20The%20felid%20purr:%20A%20healing%20mechanism?%20Session:%20Tuesday%20Afternoon,%20Dec%2004%20Time:%203:15>, and Simos et al., U.S. patent application Ser. No.11/262,884, each incorporated herein by reference. In some instances,music alterer module 2046 may include a computer processor.

Further, operation 3006 illustrates altering at least a portion ofambient noise in the artificial sensory experience. For example, asshown in FIGS. 18 through 21, ambient noise alterer module 2048 mayalter at least a portion of ambient noise in the artificial sensoryexperience. In one instance, ambient noise atterer module 2048 may alterthe ambient noise in an artificial sensory experience including a levelof white noise in the online virtual world Second Life. Ambient noisemay include white noise, background noise, such as people talking,sounds naturally occurring in nature (e.g., children laughing whiteplaying at a park), and/or room noise. Additionally, ambient noise mayinclude abnormal, non-recurring, and/or disruptive audible content, suchas gunfire. Changing the level of white noise may enhance the effect ofan attention deficit drug such as Ritalin, or it may enhance thesedative properties of a steep medication or tranquilizer. Furtherdiscussion of the effects of white noise may be found in Spencer, J. A.et al., White noise and sleep induction, ARCH DIS CHILD 65(1):135-7(1990). In some instances, ambient noise alterer module 2048 may includea computer processor.

FIG. 31 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 31 illustrates example embodiments whereoperation 2230 may include at least one additional operation. Additionaloperations may include operation 3102, and/or operation 3104.

Further, operation 3102 illustrates altering at Least a portion of voicein the artificial sensory experience. For example, as shown in FIGS. 18through 21, voice alterer module 2050 may alter at least a portion ofvoice in the artificial sensory experience. In one instance, voicealterer module 2050 may alter a voice rhythm in an online tutorial. Suchalteration may enhance the effect of an inhaled attention deficitbioactive agent, for example by elimination or reduction of monotonicqualities in the voice rhythm of the online tutorial, for example. Someexamples of a voice may include a voice recording, an artificiallygenerated voice (e.g., synthesized speech and/or voice built intoanimation simulations), and/or a human voice. In some instances, voicealterer module 2050 may include a computer processor.

Operation 3104 illustrates modifying an artificial sensory experience toalter the efficacy of the bioactive agent. For example, as shown inFIGS. 18 through 21, efficacy modifier module 2052 may modify anartificial sensory experience to enhance the efficacy of the bioactiveagent. In one embodiment, efficacy modifier module 2052 may modify avirtual world by adding uptempo music to enhance the efficacy of aninhaled antidepressant. Further discussion of music effects may be foundin Schellenberg, E. G. et al., Exposure to music and cognitiveperformance: tests of children and adults, PSYCHOLOGY OF MUSIC, Vol. 35,No. 1, 5-19 (2007), incorporated herein by reference. In some instances,efficacy modifier module 2052 may include a computer processor.

FIG. 32 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 32 illustrates example embodiments whereoperation 2230 may include at least one additional operation. Additionaloperations may include operation 3202, operation 3204, and/or operation3206.

Operation 3202 illustrates modifying an artificial sensory experience toalter a side effect of the bioactive agent. For example, as shown inFIGS. 18 through 21, side effect modifier module 2054 may modify anartificial sensory experience to alter a side effect of the bioactiveagent. In one instance, side effect modifier module 2054 may modify avirtual world by adding music and/or sounds occurring in nature forreducing a side effect, such as a headache due to an administration ofpenicillin. Further discussion of music effects upon a side effect maybe found in Siedliecki, S. L. and Good, M., Effect of music on power,pain, depression and disability, JOURNAL OF ADVANCED NURSING54(5):553-562 (2006), and Natural distractions reduce pain—study findsthat sights and sounds of nature aid in pain reduction—Brief Article,MEN'S FITNESS. October 2001, each incorporated by reference. In someinstances, side effect modifier module 2054 may include a computerprocessor.

Operation 3204 illustrates adding at least one of visual or audiocontent to the artificial sensory experience. For example, as shown inFIGS. 18 through 21, adder module 2056 may add visual and/or audiocontent to the artificial sensory experience. In one instance, addermodule 2056 may add audio content including calming music to anartificial sensory experience including a virtual world for treatingstress. Adding may include increasing, creating, and/or combiningcontent. Some examples of visual content may include visual objects,light amount and/or intensity, and or color schemes. Examples of audiocontent may include music, voices, artificial sounds, and/or whitenoise. In some instances, adder module 2056 may include a computerprocessor.

Operation 3206 illustrates deleting at least one of visual or audiocontent from the artificial sensory experience. For example, as shown inFIGS. 18 through 21, deleter module 2058 may delete at least one ofvisual or audio content of the artificial sensory experience. In oneinstance, deleter module 2058 may delete visual content including abright lighting environment in a virtual world for enhancing the effectof a medication for a migraine headache. Deleting may include reducingand/or eliminating visual and/or audio content. In some instances,deleter module 2058 may include a computer processor.

FIG. 33 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 33 illustrates example embodiments whereoperation 2230 may include at least one additional operation. Additionaloperations may include operation 3302, operation 3304, and/or operation3306.

Operation 3302 illustrates adding content to the artificial sensoryexperience and deleting different content of the artificial sensoryexperience. For example, as shown in FIGS. 18 through 21, adder module2056 and deleter module 2058 may add content to the artificial sensoryexperience and delete different content of the artificial sensoryexperience. In one instance, adder module 2056 may add classicalbackground music to a virtual world and deleter module 2058 may deleteambient street noise, for example, using sound detection and/ornoise-cancellation technology, to enhance the effect of a sedative orother similar bioactive agent. In some instances, adder module 2056and/or deleter module 2058 may include a computer processor.

Operation 3304 illustrates modifying a sensate experience. For example,as shown in FIGS. 18 through 21, sensate modifier module 2060 may modifya sensate experience, such as for altering at least one effect of thebioactive agent. In one instance, sensate modifier module 2060 maymodify a sensate experience including adding a pleasant aroma to enhancethe effect of an anxiolytic drug or other similar bioactive agent. Asensate experience may include a thing perceived by the senses, such asan aroma, a sound, a feel, a taste, and/or a sight. In some instances,sensate modifier module 2060 may include a computer processor.

Further, the operation 3306 illustrates modifying at least one of anolfactory stimulus, a haptic stimulus, a visual stimulus, an auditorystimulus, or a taste stimulus. For example, as shown in FIGS. 18 through21, stimulus modifier module 2062 may modify at least one of anolfactory stimulus, a haptic stimulus, a visual stimulus, an auditorystimulus, or a taste stimulus. In one instance, stimulus modifier module2062 may modify an olfactory stimulus by adding a floral aroma and/orgentle vibration to enhance a relaxing effect of a sedative or othersimilar bioactive agent, such as an antianxiety medication. Furtherdiscussion of an olfactory stimulus may be found in Shaw, D. et al.,Anxiolytic effects of lavender oil inhalation on open-field behaviour inrats, PHYTOMEDICINE, 14(9):613-20 (2007), incorporated by reference. Insome instances, stimulus modifier module 2062 may include a computerprocessor.

FIG. 34 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 34 illustrates example embodiments whereoperation 2230 may include at least one additional operation. Additionaloperations may include operation 3402, operation 3404, and/or operation3406.

Operation 3402 illustrates modifying an artificial sensory experienceimplemented on a mobile device. For example, as shown in FIGS. 18through 21, mobile device modifier module 2064 may modify an artificialsensory experience implemented on a mobile device. In one instance,mobile device modifier module 2064 may modify a virtual worldimplemented in a web browser on a laptop computer having wirelesscapability and a battery by changing a background color theme to abrighter color theme in the virtual world. An artificial sensoryexperience modification, such as the color change in the above example,may enhance the effect of a bioactive agent. For example, modifying thecolor in the above example white an inhaled anti-depressant isbioavailable may create a more pleasant environment in the artificialsensory experience. Some examples of a mobile device may include alaptop or notebook computer, a personal digital assistant (PDA), anipod, a smartphone, an Enterprise digital assistant (EDA), and/or apager. In another example, mobile device modifier module 2064 may modifya city image by providing a soothing image having fewer people in thesame part of the city and combining the modified image with an inhaledanti-anxiety medicine for alleviating a phobia, such as agoraphobia. Inanother example, mobile device modifier module 2064 may provide astepwise procedure, with a gradually less specific procedure and/or lesssteps, for a compulsive patient to follow to achieve a goal for aparticular outing while taking a selective serotonin reuptake inhibitor(SSRI). Data sent to or from a mobile device may be encrypted by methodsknown in the art to preserve the integrity of the data and the privacyof the individual's personal and medical information. In some instances,mobile device modifier module 2064 may include a computer processor.

Operation 3404 illustrates modifying a bioactive agent dosage. Forexample, as shown in FIGS. 18 through 21, dosage modifier module 2066may modify a bioactive agent dosage. In one embodiment, dosage modifiermodule 2066 may reduce an inhaled antianxiety dose for an individualexperiencing an artificial sensory experience and exhibiting adrastically reduced heart rate. Such a dosage reduction may serve toachieve a bioactive agent effective dose, reduce one or more detectedside effects, and/or increase efficiency of the combination bioactiveagent and artificial sensory experience. One example of reducing abioactive agent dosage using a controller in an implanted device may befound in Shelton, U.S. Patent Publication No. 2008/0172044, which isincorporated herein by reference. In some instances, dosage modifiermodule 2066 may include a computer processor and/or medicalinstrumentation.

Operation 3406 illustrates modifying at least one bioactive agent in abioactive agent combination. For example, as shown in FIGS. 18 through21, bioactive agent modifier module 2068 may modify a bioactive agent ina bioactive agent combination. A bioactive agent combination may includetwo or more bioactive agents. One example of an inhaled bioactive agentcombination may include a long acting B₂-agonist and a corticosteroid,further discussed in Usmani et al., Glucocorticoid Receptor NuclearTranslocation in Airway Cells after Inhaled Combination Therapy,AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 172:704-12(2005), which is incorporated herein by reference. In some instances,bioactive agent modifier module 2068 may include a computer processorand/or medical instrumentation.

FIG. 35 illustrates alternative embodiments of the example operationalflow 2200 of FIG. 22. FIG. 35 illustrates example embodiments whereoperation 2230 may include at least one additional operation. Additionaloperations may include operation 3502, and/or operation 3504.

Operation 3502 illustrates modifying a bioactive agent delivery method.For example, as shown in FIGS. 18 through 21, delivery modifier module2070 may modify a bioactive agent delivery method. In one embodiment,delivery modifier module 2070 may modify an antidepressant route ofadministration from an inhalation collar delivery to a inhalationbracelet delivery. Some examples of bioactive delivery methods mayinclude mucosal administration, parenterat administration (such asintravenous, intramuscular, and/or subcutaneous administration), topicaladministration such as epicutaneous administration, inhalationaladministration (e.g., inhalation collar, bracelet, tie, and/or otherdevice configured to dispense a bioactive agent for inhalation),transdermal administration, and/or enteral therapy, such as a pill takenorally, or the like. In some instances, delivery modifier module 2070may include a computer processor and/or a medical device.

Operation 3504 illustrates monitoring blood pressure of the individualwhile the individual experiences a mountainous virtual world,associating the blood pressure with the mountainous virtual world, anddynamically modifying a lighting scheme in the mountainous virtual worldin response to periodic blood pressure monitoring. For example, as shownin FIGS. 18 through 21, monitorer module 2002, associater module 2016,and modifier module 2030 may monitor blood pressure of the individualwhile the individual experiences a mountainous virtual world,associating the blood pressure with the mountainous virtual world, anddynamically modifying a Lighting scheme in the mountainous virtual worldin response to periodic blood pressure monitoring. In some instances,monitorer module 2002 may include a computer processor and/or medicalinstrumentation, such as an electrocardiograph. In some instances,associater module 2016 may include a computer processor. In someinstances, modifier module 2030 may include a computer processor and/ormedical instrumentation, such as a valve and or pump configured forpumping a bioactive agent.

FIG. 36 illustrates a partial view of an example computer programproduct 3600 that includes a computer program 3604 for executing acomputer process on a computing device. An embodiment of the examplecomputer program product 3600 is provided using a signal-bearing medium3602, and may include one or more instructions for monitoring at leastone health attribute of an individual during an artificial sensoryexperience, one or more instructions for associating a characteristic ofthe artificial sensory experience with the at least one health attributeof the individual, and one or more instructions for modifying at leastone of an inhalation device-dispensed bioactive agent or the artificialsensory experience at least partially based on associating acharacteristic of the artificial sensory experience with the at leastone health attribute of the individual. The one or more instructions maybe, for example, computer executable and/or logic-implementedinstructions. In one implementation, the signal-bearing medium 3602 mayinclude a computer-readable medium 3606. In one implementation, thesignal bearing medium 3602 may include a recordable medium 3608. In oneimplementation, the signal bearing medium 3602 may include acommunications medium 3610.

FIG. 37 illustrates an example system 3700 in which embodiments may beimplemented. The system 3700 includes a computing system environment.The system 3700 also illustrates the user 118 using a device 3704, whichis optionally shown as being in communication with a computing device3702 by way of an optional coupling 3706. The optional coupling 3706 mayrepresent a local, wide-area, or peer-to-peer network, or may representa bus that is internal to a computing device (e.g., in exampleembodiments in which the computing device 3702 is contained in whole orin part within the device 3704). A storage medium 3708 may be anycomputer storage media.

The computing device 3702 includes computer-executable instructions 3710that when executed on the computing device 3702 cause the computingdevice 3702 to monitor at least one health attribute of an individualduring an artificial sensory experience, associate a characteristic ofthe artificial sensory experience with the at least one health attributeof the individual, and modify at least one of an inhalationdevice-dispensed bioactive agent or the artificial sensory experience atleast partially based on associating a characteristic of the artificialsensory experience with the at least one health attribute of theindividual. As referenced above and as shown in FIG. 37, in someexamples, the computing device 3702 may optionally be contained in wholeor in part within the device 3704.

In FIG. 37, then, the system 3700 includes at least one computing device(e.g., 3702 and/or 3704). The computer-executable instructions 3710 maybe executed on one or more of the at least one computing device. Forexample, the computing device 3702 may implement the computer-executableinstructions 3710 and output a result to (and/or receive data from) thecomputing device 3704. Since the computing device 3702 may be wholly orpartially contained within the computing device 3704, the device 3704also may be said to execute some or all of the computer-executableinstructions 3710, in order to be caused to perform or implement, forexample, various ones of the techniques described herein, or othertechniques.

The device 3704 may include, for example, a portable computing device,workstation, or desktop computing device. In another example embodiment,the computing device 3702 is operable to communicate with the device3704 associated with the user 118 to receive information about the inputfrom the user 118 for performing data access and data processing andpresenting an output of the user-health test function at least partlybased on the user data.

Although a user 118 is shown/described herein as a single illustratedfigure, those skilled in the art will appreciate that a user 118 may berepresentative of a human user, a robotic user (e.g., computationalentity), and/or substantially any combination thereof (e.g., a user maybe assisted by one or more robotic agents). In addition, a user 118, asset forth herein, although shown as a single entity may in fact becomposed of two or more entities. Those skilled in the art willappreciate that, in general, the same may be said of “sender” and/orother entity-oriented terms as such terms are used herein.

Following are a series of flowcharts depicting implementations. For easeof understanding, the flowcharts are organized such that the initialflowcharts present implementations via an example implementation andthereafter the following flowcharts present alternate implementationsand/or expansions of the initial flowchart(s) as either sub-componentoperations or additional component operations building on one or moreearlier-presented flowcharts. Those having skill in the art willappreciate that the style of presentation utilized herein (e.g.,beginning with a presentation of a flowchart(s) presenting an exampleimplementation and thereafter providing additions to and/or furtherdetails in subsequent flowcharts) generally allows for a rapid and easyunderstanding of the various process implementations. In addition, thoseskilled in the art will further appreciate that the style ofpresentation used herein also lends itself well to modular and/orobject-oriented program design paradigms.

Those skilled in the art will appreciate that the foregoing specificexemplary processes and/or devices and/or technologies arerepresentative of more general processes and/or devices and/ortechnologies taught elsewhere herein, such as in the claims filedherewith and/or elsewhere in the present application.

Those having skill in the art will recognize that the state of the arthas progressed to the point where there is little distinction leftbetween hardware, software, and/or firmware implementations of aspectsof systems; the use of hardware, software, and/or firmware is generally(but not always, in that in certain contexts the choice between hardwareand software can become significant) a design choice representing costvs. efficiency tradeoffs. Those having skill in the art will appreciatethat there are various vehicles by which processes and/or systems and/orother technologies described herein can be effected (e.g., hardware,software, and/or firmware), and that the preferred vehicle will varywith the context in which the processes and/or systems and/or othertechnologies are deployed. For example, if an implementer determinesthat speed and accuracy are paramount, the implementer may opt for amainly hardware and/or firmware vehicle; alternatively, if flexibilityis paramount, the implementer may opt for a mainly softwareimplementation; or, yet again alternatively, the implementer may opt forsome combination of hardware, software, and/or firmware. Hence, thereare several possible vehicles by which the processes and/or devicesand/or other technologies described herein may be effected, none ofwhich is inherently superior to the other in that any vehicle to beutilized is a choice dependent upon the context in which the vehiclewill be deployed and the specific concerns (e.g., speed, flexibility, orpredictability) of the implementer, any of which may vary. Those skilledin the art will recognize that optical aspects of implementations willtypically employ optically-oriented hardware, software, and or firmware.

In some implementations described herein, logic and similarimplementations may include software or other control structuressuitable to operation. Electronic circuitry, for example, may manifestone or more paths of electrical current constructed and arranged toimplement various logic functions as described herein. In someimplementations, one or more media are configured to bear adevice-detectable implementation if such media hold or transmit aspecial-purpose device instruction set operable to perform as describedherein. In some variants, for example, this may manifest as an update orother modification of existing software or firmware, or of gate arraysor other programmable hardware, such as by performing a reception of ora transmission of one or more instructions in relation to one or moreoperations described herein. Alternatively or additionally, in somevariants, an implementation may include special-purpose hardware,software, firmware components, and/or general-purpose componentsexecuting or otherwise invoking special-purpose components.Specifications or other implementations may be transmitted by one ormore instances of tangible transmission media as described herein,optionally by packet transmission or otherwise by passing throughdistributed media at various times.

Alternatively or additionally, implementations may include executing aspecial-purpose instruction sequence or otherwise invoking circuitry forenabling, triggering, coordinating, requesting, or otherwise causing oneor more occurrences of any functional operations described above. Insome variants, operational or other logical descriptions herein may beexpressed directly as source code and compiled or otherwise invoked asan executable instruction sequence. In some contexts, for example, C++or other code sequences can be compiled directly or otherwiseimplemented in high-level descriptor languages (e.g., alogic-synthesizable language, a hardware description language, ahardware design simulation, and/or other such similar mode(s) ofexpression). Alternatively or additionally, some or all of the logicalexpression may be manifested as a Verilog-type hardware description orother circuitry model before physical implementation in hardware,especially for basic operations or timing-critical applications. Thoseskilled in the art will recognize how to obtain, configure, and optimizesuitable transmission or computational elements, material supplies,actuators, or other common structures in light of these teachings.

The foregoing detailed description has set forth various embodiments ofthe devices and/or processes via the use of block diagrams, flowcharts,and/or examples. Insofar as such block diagrams, flowcharts, and/orexamples contain one or more functions and/or operations, it will beunderstood by those within the art that each function and/or operationwithin such block diagrams, flowcharts, or examples can be implemented,individually and/or collectively, by a wide range of hardware, software,firmware, or virtually any combination thereof. In one embodiment,several portions of the subject matter described herein may beimplemented via Application Specific Integrated Circuits (ASICs), FieldProgrammable Gate Arrays (FPGAs), digital signal processors (DSPs), orother integrated formats. However, those skilled in the art willrecognize that some aspects of the embodiments disclosed herein, inwhole or in part, can be equivalently implemented in integratedcircuits, as one or more computer programs running on one or morecomputers (e.g., as one or more programs running on one or more computersystems), as one or more programs running on one or more processors(e.g., as one or more programs running on one or more microprocessors),as firmware, or as virtually any combination thereof, and that designingthe circuitry and/or writing the code for the software and or firmwarewould be well within the skill of one of skill in the art in light ofthis disclosure. In addition, those skilled in the art will appreciatethat the mechanisms of the subject matter described herein are capableof being distributed as a program product in a variety of forms, andthat an illustrative embodiment of the subject matter described hereinapplies regardless of the particular type of signal bearing medium usedto actually carry out the distribution. Examples of a signal bearingmedium include, but are not limited to, the following: a recordable typemedium such as a floppy disk, a hard disk drive, a Compact Disc (CD), aDigital Video Disk (DVD), a digital tape, a computer memory, etc.; and atransmission type medium such as a digital and/or an analogcommunication medium (e.g., a fiber optic cable, a waveguide, a wiredcommunications link, a wireless communication link (e.g., transmitter,receiver, transmission logic, reception Logic, etc.), etc.).

In a general sense, those skilled in the art will recognize that thevarious embodiments described herein can be implemented, individuallyand/or collectively, by various types of electro-mechanical systemshaving a wide range of electrical components such as hardware, software,firmware, and/or virtually any combination thereof; and a wide range ofcomponents that may impart mechanical force or motion such as rigidbodies, spring or torsional bodies, hydraulics, electro-magneticallyactuated devices, and/or virtually any combination thereof.ConsequentLy, as used herein “electro-mechanical system” includes, butis not limited to, electrical circuitry operably coupled with atransducer (e.g., an actuator, a motor, a piezoelectric crystal, a MicroElectro Mechanical System (MEMS), etc.), electrical circuitry having atleast one discrete electrical circuit, electrical circuitry having atleast one integrated circuit, electrical circuitry having at least oneapplication specific integrated circuit, electrical circuitry forming ageneral purpose computing device configured by a computer program (e.g.,a general purpose computer configured by a computer program which atleast partially carries out processes and/or devices described herein,or a microprocessor configured by a computer program which at leastpartially carries out processes and/or devices described herein),electrical circuitry forming a memory device (e.g., forms of memory(e.g., random access, flash, read only, etc.)), electrical circuitryforming a communications device (e.g., a modem, communications switch,optical-electrical equipment, etc.), and/or any non-electrical analogthereto, such as optical or other analogs. Those skilled in the art willalso appreciate that examples of electro-mechanical systems include butare not limited to a variety of consumer electronics systems, medicaldevices, as well as other systems such as motorized transport systems,factory automation systems, security systems, and/orcommunication/computing systems. Those skilled in the art will recognizethat electromechanical as used herein is not necessarily limited to asystem that has both electrical and mechanical actuation except ascontext may dictate otherwise.

In a general sense, those skilled in the art will recognize that thevarious aspects described herein which can be implemented, individuallyand/or collectively, by a wide range of hardware, software, firmware,and/or any combination thereof can be viewed as being composed ofvarious types of “electrical circuitry.” Consequently, as used herein“electrical circuitry” includes, but is not limited to, electricalcircuitry having at least one discrete electrical circuit, electricalcircuitry having at least one integrated circuit, electrical circuitryhaving at least one application specific integrated circuit, electricalcircuitry forming a general purpose computing device configured by acomputer program (e.g., a general purpose computer configured by acomputer program which at least partially carries out processes and/ordevices described herein, or a microprocessor configured by a computerprogram which at least partially carries out processes and/or devicesdescribed herein), electrical circuitry forming a memory device (e.g.,forms of memory (e.g., random access, flash, read only, etc.)), and/orelectrical circuitry forming a communications device (e.g., a modem,communications switch, optical-electrical equipment, etc.). Those havingskill in the art will recognize that the subject matter described hereinmay be implemented in an analog or digital fashion or some combinationthereof.

Those skilled in the art will recognize that at least a portion of thedevices and/or processes described herein can be integrated into a dataprocessing system. Those having skill in the art will recognize that adata processing system generally includes one or more of a system unithousing, a video display device, memory such as volatile or non-volatilememory, processors such as microprocessors or digital signal processors,computational entities such as operating systems, drivers, graphicaluser interfaces, and applications programs, one or more interactiondevices (e.g., a touch pad, a touch screen, an antenna, etc.), and/orcontrol systems including feedback loops and control motors (e.g.,feedback for sensing position and/or velocity; control motors for movingand/or adjusting components and/or quantities). A data processing systemmay be implemented utilizing suitable commercially available components,such as those typically found in data computing/communication and/ornetwork computing/communication systems.

Those skilled in the art will recognize that it is common within the artto implement devices and/or processes and/or systems, and thereafter useengineering and/or other practices to integrate such implemented devicesand/or processes and/or systems into more comprehensive devices and/orprocesses and/or systems. That is, at least a portion of the devicesand/or processes and/or systems described herein can be integrated intoother devices and/or processes and/or systems via a reasonable amount ofexperimentation. Those having skill in the art will recognize thatexamples of such other devices and/or processes and/or systems mightinclude—as appropriate to context and application—all or part of devicesand/or processes and/or systems of (a) an air conveyance (e.g., anairplane, rocket, helicopter, etc.), (b) a ground conveyance (e.g., acar, truck, locomotive, tank, armored personnel carrier, etc.), (c) abuilding (e.g., a home, warehouse, office, etc.), (d) an appliance(e.g., a refrigerator, a washing machine, a dryer, etc.), (e) acommunications system (e.g., a networked system, a telephone system, aVoice over IP system, etc.), (f) a business entity (e.g., an InternetService Provider (ISP) entity such as Comcast Cable, Qwest, SouthwesternBell, etc.), or (g) a wired/wireless services entity (e.g., Sprint,Cingular, Nextel, etc.), etc.

In certain cases, use of a system or method may occur in a territoryeven if components are located outside the territory. For example, in adistributed computing context, use of a distributed computing system mayoccur in a territory even though parts of the system may be locatedoutside of the territory (e.g., relay, server, processor, signal-bearingmedium, transmitting computer, receiving computer, etc. located outsidethe territory).

A sale of a system or method may Likewise occur in a territory even ifcomponents of the system or method are located and/or used outside theterritory.

Further, implementation of at least part of a system for performing amethod in one territory does not preclude use of the system in anotherterritory.

All of the above U.S. patents, U.S. patent application publications,U.S. patent applications, foreign patents, foreign patent applicationsand non-patent publications referred to in this specification and/orlisted in any Application Data Sheet, are incorporated herein byreference, to the extent not inconsistent herewith.

One skilled in the art will recognize that the herein describedcomponents (e.g., operations), devices, objects, and the discussionaccompanying them are used as examples for the sake of conceptualclarity and that various configuration modifications are contemplated.Consequently, as used herein, the specific exemplars set forth and theaccompanying discussion are intended to be representative of their moregeneral classes. In general, use of any specific exemplar is intended tobe representative of its class, and the non-inclusion of specificcomponents (e.g., operations), devices, and objects should not be takenLimiting.

Although user 118 is shown/described herein as a single illustratedfigure, those skilled in the art will appreciate that user 118 may berepresentative of a human user, a robotic user (e.g., computationalentity), and/or substantially any combination thereof (e.g., a user maybe assisted by one or more robotic agents) unless context dictatesotherwise. Those skilled in the art will appreciate that, in general,the same may be said of “sender” and/or other entity-oriented terms assuch terms are used herein unless context dictates otherwise.

With respect to the use of substantially any plural and/or singularterms herein, those having skill in the art can translate from theplural to the singular and/or from the singular to the plural as isappropriate to the context and/or application. The varioussingular/plural permutations are not expressly set forth herein for sakeof clarity.

The herein described subject matter sometimes illustrates differentcomponents contained within, or connected with, different othercomponents. It is to be understood that such depicted architectures aremerely exemplary, and that in fact many other architectures may beimplemented which achieve the same functionality. In a conceptual sense,any arrangement of components to achieve the same functionality iseffectively “associated” such that the desired functionality isachieved. Hence, any two components herein combined to achieve aparticular functionality can be seen as “associated with” each othersuch that the desired functionality is achieved, irrespective ofarchitectures or intermedial components. Likewise, any two components soassociated can also be viewed as being “operably connected”, or“operably coupled,” to each other to achieve the desired functionality,and any two components capable of being so associated can also be viewedas being “operably couplable,” to each other to achieve the desiredfunctionality. Specific examples of operably couplable include but arenot limited to physically mateable and/or physically interactingcomponents, and/or wirelessly interactable, and/or wirelesslyinteracting components, and/or logically interacting, and/or logicallyinteractable components.

In some instances, one or more components may be referred to herein as“configured to,” “configurable to,” “operable/operative to,”“adapted/adaptable,” “able to,” “conformable/conformed to,” etc. Thoseskilled in the art will recognize that “configured to” can generallyencompass active-state components and/or inactive-state componentsand/or standby-state components, unless context requires otherwise.

While particular aspects of the present subject matter described hereinhave been shown and described, it will be apparent to those skilled inthe art that, based upon the teachings herein, changes and modificationsmay be made without departing from the subject matter described hereinand its broader aspects and, therefore, the appended claims are toencompass within their scope all such changes and modifications as arewithin the true spirit and scope of the subject matter described herein.It will be understood by those within the art that, in general, termsused herein, and especially in the appended claims (e.g., bodies of theappended claims) are generally intended as “open” terms (e.g., the term“including” should be interpreted as “including but not limited to,” theterm “having” should be interpreted as “having at least,” the term“includes” should be interpreted as “includes but is not limited to,”etc.). It will be further understood by those within the art that if aspecific number of an introduced claim recitation is intended, such anintent will be explicitly recited in the claim, and in the absence ofsuch recitation no such intent is present. For example, as an aid tounderstanding, the following appended claims may contain usage of theintroductory phrases “at least one” and “one or more” to introduce claimrecitations. However, the use of such phrases should not be construed toimply that the introduction of a claim recitation by the indefinitearticles “a” or “an” limits any particular claim containing suchintroduced claim recitation to claims containing only one suchrecitation, even when the same claim includes the introductory phrases“one or more” or “at least one” and indefinite articles such as “a” or“an” (e.g., “a” and/or “an” should typically be interpreted to mean “atleast one” or “one or more”); the same holds true for the use ofdefinite articles used to introduce claim recitations. In addition, evenif a specific number of an introduced claim recitation is explicitlyrecited, those skilled in the art will recognize that such recitationshould typically be interpreted to mean at least the recited number(e.g., the bare recitation of “two recitations,” without othermodifiers, typically means at least two recitations, or two or morerecitations). Furthermore, in those instances where a conventionanalogous to “at least one of A, B, and C, etc.” is used, in generalsuch a construction is intended in the sense one having skill in the artwould understand the convention (e.g., “a system having at least one ofA, B, and C” would include but not be limited to systems that have Aatone, B atone, C alone, A and B together, A and C together, B and Ctogether, and/or A, B, and C together, etc.). In those instances where aconvention analogous to “at least one of A, B, or C, etc.” is used, ingeneral such a construction is intended in the sense one having skill inthe art would understand the convention (e.g., “a system having at leastone of A, B, or C” would include but not be Limited to systems that haveA alone, B alone, C alone, A and B together, A and C together, B and Ctogether, and/or A, B, and C together, etc.). It will be furtherunderstood by those within the art that typically a disjunctive wordand/or phrase presenting two or more alternative terms, whether in thedescription, claims, or drawings, should be understood to contemplatethe possibilities of including one of the terms, either of the terms, orboth terms unless context dictates otherwise. For example, the phrase “Aor B” will be typically understood to include the possibilities of “A”or “B” or “A and B.”

With respect to the appended claims, those skilled in the art willappreciate that recited operations therein may generally be performed inany order. Also, although various operational flows are presented in asequence(s), it should be understood that the various operations may beperformed in other orders than those which are illustrated, or may beperformed concurrently. Examples of such alternate orderings may includeoverlapping, interleaved, interrupted, reordered, incremental,preparatory, supplemental, simultaneous, reverse, or other variantorderings, unless context dictates otherwise. Furthermore, terms like“responsive to,” “related to,” or other past-tense adjectives aregenerally not intended to exclude such variants, unless context dictatesotherwise.

While various aspects and embodiments have been disclosed herein, otheraspects and embodiments will be apparent to those skilled in the art.The various aspects and embodiments disclosed herein are for purposes ofillustration and are not intended to be limiting, with the true scopeand spirit being indicated by the following claims.

1-78. (canceled)
 79. A system, comprising: a monitorer module; anassociater module; and a modifier module configured to modify at leastone of an inhalation device-dispensed bioactive agent or an artificialsensory experience at least partially based on associating acharacteristic of the artificial sensory experience with at least onehealth attribute of an individual.
 80. The system of claim 79, whereinthe monitorer module comprises: a data receiver module.
 81. The systemof claim 79, wherein the monitorer module comprises: a health attributemonitorer module.
 82. The system of claim 79, wherein the monitorermodule comprises: a neurophysiological monitorer module.
 83. The systemof claim 82, wherein the neurophysiological monitorer module comprises:a neurophysiological measurer module.
 84. The system of claim 79,wherein the monitorer module comprises: a recorder module.
 85. Thesystem of claim 79, wherein the monitorer module comprises: an observermodule.
 86. The system of claim 79, wherein the associater modulecomprises: a physiological response associater module.
 87. The system ofclaim 86, wherein the physiological response associater modulecomprises: an artificial sensory experience associater module.
 88. Thesystem of claim 86, wherein the physiological response associater modulecomprises: a health attribute associater module.
 89. The system of claim79, wherein the associater module comprises: a report accepter module.90. The system of claim 79, wherein the associater module comprises: autilizer module.
 91. The system of claim 79, wherein the associatermodule comprises: a comparer module.
 92. The system of claim 79, whereinthe modifier module configured to modify at least one of an inhalationdevice-dispensed bioactive agent or an artificial sensory experience atleast partially based on associating a characteristic of the artificialsensory experience with at least one health attribute of an individualcomprises: an access modifier module.
 93. The system of claim 92,wherein the access modifier module comprises: a restricter module. 94.The system of claim 92, wherein the access modifier module comprises: agranter module.
 95. The system of claim 79, wherein the modifier moduleconfigured to modify at least one of an inhalation device-dispensedbioactive agent or an artificial sensory experience at least partiallybased on associating a characteristic of the artificial sensoryexperience with at least one health attribute of an individualcomprises: a visual object modifier module.
 96. The system of claim 95,wherein the visual object modifier module comprises: a color schememodifier module.
 97. The system of claim 95, wherein the visual objectmodifier module comprises: a text modifier module.
 98. The system ofclaim 79, wherein the modifier module configured to modify at least oneof an inhalation device-dispensed bioactive agent or an artificialsensory experience at least partially based on associating acharacteristic of the artificial sensory experience with at least onehealth attribute of an individual comprises: a sound alterer module. 99.The system of claim 98, wherein the sound alterer module comprises: amusic alterer module.
 100. The system of claim 98, wherein the soundalterer module comprises: an ambient noise alterer module.
 101. Thesystem of claim 98, wherein the sound alterer module comprises: a voicealterer module.
 102. The system of claim 79, wherein the modifier moduleconfigured to modify at least one of an inhalation device-dispensedbioactive agent or an artificial sensory experience at least partiallybased on associating a characteristic of the artificial sensoryexperience with at least one health attribute of an individualcomprises: an efficacy modifier module.
 103. The system of claim 79,wherein the modifier module configured to modify at least one of aninhalation device-dispensed bioactive agent or an artificial sensoryexperience at least partially based on associating a characteristic ofthe artificial sensory experience with at least one health attribute ofan individual comprises: a side effect modifier module.
 104. The systemof claim 79, wherein the modifier module configured to modify at leastone of an inhalation device-dispensed bioactive agent or an artificialsensory experience at least partially based on associating acharacteristic of the artificial sensory experience with at least onehealth attribute of an individual comprises: an adder module.
 105. Thesystem of claim 79, wherein the modifier module configured to modify atleast one of an inhalation device-dispensed bioactive agent or anartificial sensory experience at least partially based on associating acharacteristic of the artificial sensory experience with at least onehealth attribute of an individual comprises: a deleter module.
 106. Thesystem of claim 79, wherein the modifier module configured to modify atleast one of an inhalation device-dispensed bioactive agent or anartificial sensory experience at least partially based on associating acharacteristic of the artificial sensory experience with at least onehealth attribute of an individual comprises: a sensate modifier module.107. The system of claim 106, wherein the sensate modifier modulecomprises: a stimulus modifier module.
 108. The system of claim 79,wherein the modifier module configured to modify at least one of aninhalation device-dispensed bioactive agent or an artificial sensoryexperience at least partially based on associating a characteristic ofthe artificial sensory experience with at least one health attribute ofan individual comprises: a mobile device modifier module.
 109. Thesystem of claim 79, wherein the modifier module configured to modify atleast one of an inhalation device-dispensed bioactive agent or anartificial sensory experience at least partially based on associating acharacteristic of the artificial sensory experience with at least onehealth attribute of an individual comprises: a dosage modifier module.110. The system of claim 79, wherein the modifier module configured tomodify at least one of an inhalation device-dispensed bioactive agent oran artificial sensory experience at least partially based on associatinga characteristic of the artificial sensory experience with at least onehealth attribute of an individual comprises: a bioactive agent modifiermodule.
 111. The system of claim 79, wherein the modifier moduleconfigured to modify at least one of an inhalation device-dispensedbioactive agent or an artificial sensory experience at least partiallybased on associating a characteristic of the artificial sensoryexperience with at least one health attribute of an individualcomprises: a delivery modifier module.